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The metabolic syndrome, low folate 
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may be associated with depression. 
However, the impact of melancholic or 
non-melancholic depressive symptoms 
has not been evaluated. 
The results of this study support the 
use of the Beck Depression Inventory 
as a screening tool for depressive 
symptoms. A higher risk of the 
metabolic syndrome was associated 
with non-melancholic depressive 
symptoms.  In addition, those with a 
lower folate intake or lower vitamin 
B12 levels had a higher risk of 
melancholic depressive symptoms. 
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ABSTRACT
The predictive value of the Beck Depression Inventory (BDI) for the detection of depression
in the general population has not been extensively evaluated. Depression may be associated
with  an  increased  risk  of  the  metabolic  syndrome  (MetS)  and  with  a  low  folate  intake  or
lower vitamin B12 levels. However, the impact of melancholic or non-melancholic depressive
symptoms (DS) has not been examined.
 The aims of this population-based study were to evaluate the value of the BDI as a
screening instrument for depression, and to investigate the associations between
predominantly melancholic or non-melancholic DS measured by the BDI and the MetS,
folate intake, or serum vitamin B12 levels.
The study population (N = 2840) was selected from the National Population Register in
2007.
 A  score  of  15  in  the  BDI  simultaneously  maximized  the  sensitivity  and  specificity  of
detecting depression.
The risk for the MetS was two-fold higher in subjects with predominantly non-melancholic
DS.
 On the other hand, the risk for melancholic DS was almost 50% lower for the high folate
intake tertile versus the lowest.
 The relative risk ratio for melancholic DS was almost three-fold higher in the lowest
vitamin B12 level tertile when compared to the highest.
 This study demonstrated that the BDI with a cut-off score of 15 is a valid instrument for
screening depression in population-based subjects.
 These results suggest that liability to the MetS is particularly associated with non-
melancholic  DS,  which  may  suggest  possible  differences  in  susceptibility  to  the  MetS  in
different types of DS. The findings of the present study also suggest that folate intake and
vitamin  B12 may contribute to the pathogenesis of DS, which may be associated with
melancholic characteristics.
National Library of Medicine Classification: QT 235, QU 188, QU 194, WK 810, WM 171.5,
Medical Subject Headings:
Depression; Depression; Depressive disorder; Diet; Folic Acid; Metabolic syndrome X; Vitamin B 12
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TIIVISTELMÄ
Beckin depressioasteikon (BDI) ennustearvoa tunnistaa depressio väestötasolla ei ole
tutkittu laajalti. Kohonnut metabolisen oireyhtymän (MBO) riski sekä alentunut foolihapon
saanti tai matala B12 vitamiinin pitoisuus voivat liittyä masennukseen. Melankolisten tai ei-
melankolisten masennusoireiden vaikutusta ei ole kuitenkaan tutkittu.
 Tämän väestötutkimuksen tarkoituksena oli arvioida BDI:n kykyä seuloa masennusta
sekä BDI:llä mitattujen pääosin melankolisten tai ei-melankolisten masennusoireiden ja
MBO:n, foolihapon saannin sekä B12 vitamiinin pitoisuuden välisiä yhteyksiä.
 Tutkimusaineisto (N=2840) kerättiin väestörekisteristä vuonna 2007.
BDI:n pistemäärä 15 maksimoi samanaikaisesti sekä sensitiivisyyden että spesifisyyden
masennuksen toteamisessa.
 MBO:n riski oli yli 2x korkeampi niillä, joilla oli pääosin ei-melankolisia masennusoireita.
Toisaalta melankolisten masennusoireiden riski oli lähes 50 % alhaisempi korkean
foolihapon saannin yhteydessä suhteessa matalimpaan.
 Matalimman B12 vitamiinipitoisuuden ryhmässä melankolisten masennusoireiden
suhteellinen riski oli liki kolminkertainen verrattuna korkeimpaan ryhmään.
 Tämän tutkimuksen perusteella BDI:n pistemäärä 15 on perusteltu väestön depression
seulonnassa. Näiden tulosten pohjalta voi olla mahdollista, että taipumus MBO:hon liittyisi
erityisesti ei-melankolisiin masennusoireisiin. Tämä saattaa viitata siihen, että alttius
MBO:hon on ehkä erilainen eri masennusoireissa.
 Nykyisen tutkimuksen löydökset voivat myös tukea foolihapon ja B12 vitamiinin osuutta
masennuksen patogeneesissä, mikä saattaa liittyä melankolisiin piirteisiin.
Luokitus:
Yleinen Suomalainen asiasanasto: B12-vitamiini; foolihappo; masennus; melankolia; metabolinen oireyhtymä;
ruokavaliot
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1 INTRODUCTION
Major depression is a common disorder in the general population (Ayoso-Mateos et al.
2001, Kessler et al. 1994, Kessler et al. 2003). It frequently has a tendency towards a
recurrent or chronic course, significantly impairing the quality of life and being among the
most important causes of the disease burden and years lost due to disability (Murray et al.
1996). In the Finnish population, the 12-month prevalence of major depressive episodes
was reported to be 9.3% (Lindeman et al. 2000). Depressive disorders were found in 6.5% of
the subjects in the Finnish Health 2000 Study (Pirkola et al. 2005). The lifetime prevalence of
depressive disorders was almost 18% in the latest Finnish study among younger
population subjects (Suvisaari et al. 2009).
The  Beck  Depression  Inventory  (BDI)  is  the  most  commonly  used  self-rating  scale  for
depression, and the literature on the psychometric properties of the BDI in both clinical and
non-clinical samples/settings as well as across different countries is extensive (Beck et al.
1988). The cut-off score of 10 points in the BDI has been shown to be useful for detecting
depressive symptoms in various adult populations (Timonen et al. 2006, Räikkönen et al.
2007, Vanhala et al. 2009, Koponen et al. 2010, Korniloff et al. 2010, Mäntyselkä et al. 2011).
In  order  to  examine  the  impact  of  the  subtype  of  depressive  symptoms  (DS),  a  DSM-IV
criteria-based  summary  score  of  melancholic  symptoms  in  the  BDI  has  been  applied  to
divide the participants with increased DS into melancholic and non-melancholic subgroups
(Sheehan et al. 1994, Steer et al. 1999, Ovaskainen et al. 2009, Vanhala et al. 2009). However,
only two studies have examined the predictive value of the BDI for the detection of
depression in a representative sample of the general population and have applied a reliable
psychiatric interview as a validation instrument (Lasa et al. 2000, Nuevo et al. 2009).
The metabolic syndrome (MetS) is a cardio metabolic risk cluster comprising abdominal
obesity, altered glucose and lipid metabolism, and elevated blood pressure (Expert panel,
2001, Alberti et al. 2005, Grundy et al. 2005, Alberti et al. 2006). Applying the criteria based
on the National Cholesterol Education Programme (NCEP), the age-adjusted prevalence of
the MetS has been estimated to be approximately 35% in the US population and 37% in
Eastern Finland (Ford 2005, Miettola 2008). It has been shown to associate with an
increased risk of cardiovascular diseases, type 2 diabetes mellitus and all-cause mortality
(Lakka et al. 2002, Ford 2005). Most previous cross-sectional studies have demonstrated
that the MetS is more common in those with major depression or DS than in non-depressed
subjects, and the observed prevalence rates have varied from 8% to 38% (Kinder et al. 2004,
Heiskanen et al. 2006, Räikkönen et al. 2007, Skilton et al. 2007). However, two recent
studies have found no correlation between depression and the MetS (Hildrum et al. 2009,
Foley et al. 2010). Depression may also be a risk factor for several components of the MetS.
On the other hand, only a few studies have evaluated the relationship between the MetS
and its components and subtypes of DS (Lamers et al. 2010, Vanhala et al. 2009). The only
longitudinal study reporting the risk of metabolic syndrome in various subtypes of DS has
been the subgroup analysis of Vanhala and co-workers, who detected the highest risk for
the MetS among women only in a subgroup with more melancholic DS (Vanhala et al.
2009).
Only a few cross-sectional studies have reported an association between a low folate
intake and depression (Tolmunen et al. 2003, Sanchez-Villegas et al. 2009, Murakami et al.
2010). Of the three published prospective studies, one reported a 3-fold increased risk of
depression in men with a low folate intake (Tolmunen et al. 2004), and another
demonstrated a 75% reduced risk of recurrent depression among middle-aged men with an
increased folate intake (Astorg et al. 2008). On the other hand, a recent U.S. population-
based study reported that the intake of folate was not associated with DS (Skarupski et al.
22010). No studies have evaluated the correlation between folate intake and subtypes of
depression.
Vitamin B12 levels and DS or depressive disorders have been associated in some studies
(Penninx et al. 2000, Tiemeier et al. 2002, Kim et al. 2008, Ng et al. 2009), but inconsistent
results exist (Lindeman et al. 2000, Morris et al. 2003, Bjelland et al. 2003, Sachdev et al.
2004, Beydoun et al. 2010). The relationship between vitamin B12 levels and different
subtypes of DS has not been evaluated in previous studies.
This population-based study was undertaken to evaluate the value of the BDI as a
screening instrument for depression and the depressive symptom profile, using the clinical
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)-based Mini-International
Neuropsychiatric Interview (MINI) as a validating measure. It further aimed to investigate
the associations between predominantly melancholic or non-melancholic DS measured by
the BDI and the MetS or folate intake and serum vitamin B12 levels in a population-based
study. The study population was selected from the National Population Register of Finland
in August 2007, and comprised subjects aged 45–74 years, stratified according to gender
and 10-year age groups (45–54, 55–64 and 65–74 years), from the hospital districts of
Pirkanmaa, Southern Ostrobothnia and Central Finland.
32 REVIEW OF THE LITERATURE
2.1 Terminology
In the following review of the literature and discussion sections, the term depression covers
both studies on depressive disorders and patients with increased depressive symptoms
(DS).
2.1.1 Screening of depression
2.1.1.1 Diagnostic psychiatric interviews for adults
Besides depression-rating scales, several diagnostic interviews were initially developed to
provide reliable diagnoses for clinical research on patients with particular mental
disorders. Later, to obtain reliable data on the prevalence of mental disorders in the general
population, interviews were more focused on being useful in epidemiological community
studies. Today, most patients with psychiatric disorders are treated in primary care.
Therefore, two of the interviews included here, the Primary Care Evaluation of Mental
Disorders  (PRIME-MD)  and  the  Symptom-Driven  Diagnostic  System  for  Primary  Care
(SDDS-PC), were developed to address the need for better recognition of mental disorders
among  primary  care  physicians.  Their  main  output  is  a  determination  of  whether  the
patient’s clinical picture meets the diagnostic criteria for one of the psychiatric disorders
covered by the instrument (Handbook of Psychiatric Measures 2000). The characteristics of
the most common diagnostic interviews are presented in Table 1.
Table 1. Diagnostic interviews
Diagnostic interview
instrument
Disorder assessed Format
Structured Clinical Interview for
DSM-IV Axis I Disorders (SCID-I),
Patient edition (SCID-I/P),
Nonpatient edition (SCID-I/NP),
Clinical version (SCID-CV)
(Handbook of Psychiatric
Measures 2000).
Psychiatric disorders according to
the DSM-IV
Clinician-administered,
semistructured interview with
seven diagnostic modules
Schedules for Clinical Assessment
in Neuropsychiatry (SCAN) (World
Health Organisation 1994)
Psychopathology and behaviour
associated with a broad range of
major psychiatric disorders of
adult life, including the ICD-10
and DSM-IV, among others
SCAN interview text, Item Group
Checklist, and Clinical History
Schedule, glossary of differential
definitions, and CATEGO-5
computer program
Schedule for Affective Disorders
and Schizophrenia (SADS)
(Endicott and Spitzer 1978,
Spitzer et al. 1978)
Mental disorders as defined by
Research Diagnostic Criteria
(RDC)
Clinician-administered interview,
first part on symptoms and
second part on the history of
mental disorders
Diagnostic Interview Schedule
(DIS) (Robins et al. 1981)
Composite International
Diagnostic Interview (CIDI)
(Robins et al. 1988)
Current and lifetime psychiatric
disorders according to the DSM-
IV
Expanded DIS for use across
cultures according to the DSM-IV
and ICD-10
Highly structured interview
containing both a demographic
section and diagnostic modules
for administration by laypersons
Primary Care Evaluation of Mental
Disorders (PRIME-MD)
(Spitzer et al. 1994)
For primary care doctors in
diagnosing the most commonly
seen adult mental disorders such
as depression or anxiety in
primary health care settings
1-page Patient Questionnaire (PQ)
and 9-page Clinician Evaluation
Guide (CEG)
Symtom-Driven Diagnostic
System for Primary Care (SDDS-
PC) (Olfson et al. 1995,
Weissman et al. 1995)
Computerized tool for the
detection, diagnosis and
management of mental disorders
such as depression or anxiety in
primary health care settings
29-item patient self-report
screening questionnaire, a
diagnostic interview guide
containing an extra module for
suicide risk, and a longitudinal
tracking form
42.1.1.2 Depression scales
The most common goal of assessment is to measure the severity of depressive symptoms,
in terms of both the severity of individual symptoms and the total number of mood-related
symptoms that have been present. Depression scales are also used to detect or exclude
depressive disorders, as well as for the follow-up of recovery after treatment interventions.
They can be divided into self- or observer-rated scales (Table 2) (Handbook of Psychiatric
Measures 2000). The Hamilton Rating Scale for Depression (HAM-D) was originally
described for use in assessing the symptoms of patients diagnosed as suffering from
depressive states. It has 17 to 21 items, depending on the version, that are rated according
to  intensity  and  frequency  within  the  previous  few  days.  The  scores  for  each  item  range
from 0 to 2 or from 0 to 4 (Hamilton 1960). It includes somatic manifestations of depression,
and is the most widely used scale in treatment studies on depression (Kaplan and Sadock
2009).
The Montgomery-Åsberg Depression Rating Scale (MADRS) contains 10 items, each of
which is scored from 0 to 6 (overall range 0–60 points) (Montgomery and Åsberg 1979). The
MADRS was specifically designed to be sensitive to changes over time (Montgomery and
Åsberg 1979). It is a widely used scale with high face validity. In addition, its validity has
been demonstrated by its high correlations with the HAM-D (Kaplan and Sadock 2009). In
the Center for Epidemiologic Studies Depression Scale (CES-D), scores range from 0 to 60,
and higher scores indicate more severe depressive symptoms (Radloff 1977). In the Raskin
Scale the total depression severity score may range from 3 to 15 (Raskin 1988).
The Zung Self-Rating Depression Scale (Zung SDS) includes 20 items that are rated
according to their frequency of occurrence (Zung 1965). The Inventory of Depressive
Symptomatology (IDS) is unique among depression rating scales in that a self-report form
(IDS-SR) and a clinician-administered form (IDS-C) were developed simultaneously (Rush
et al. 1985).
5Table 2. Depression rating scales
Instrument Rater Disorder or construct assessed
Hamilton Rating Scale for
Depression (HAM-D) (Hamilton
1960)
Professional, 17 items Severity of depressive symptoms
in patients with primary
depressive illness
Montgomery-Åsberg Depression
Rating Scale (MADRS)
(Montgomery and Åsberg 1979)
Professional, 10 items Severity of depressive symptoms
Center for Epidemiologic Studies
Depression Scale (CES-D)
(Radloff 1977)
Self, 20 items Severity of depressive symptoms
in community populations
Raskin Scale (Three-Area Severity
of Depression Scale)
(Raskin 1988)
Professional, 3 items Severity of depression in three
domains: subjective experience,
behavioural manifestations, and
secondary signs of depression
Zung Self-Rating Depression
Scale (Zung SDS) (Zung 1965)
Self, 20 items Severity of depressive symptoms
Beck Depression Inventory (BDI)
(Beck et al. 1961)
Self, 21 items Severity of depressive symptoms.
Inventory of Depressive
Symptomatology (IDS)
Self-report version (IDS-SR)
Clinician-administered version
(IDS-C) (Rush et al. 1985)
Self (IDS-SR) or professional
(IDS-C), 28- and 30-item
versions
Severity of signs and symptoms
of depression including all DSM-IV
criteria items
Three of the scales presented in this table (the BDI, CES-D and Zung SDS) are also targeted
for  screening  depressive  disorders  among  in  the  community  or  in  general  medical
populations. This strategy requires a two-stage approach: the first-stage screen identifies
persons likely to have a mood disorder, and those patients screened then will be evaluated
in a second clinical diagnostic interview (Handbook of Psychiatric Measures 2000).
2.1.1.3 Mini
The  Mini-International  Neuropsychiatric  Interview  (MINI)  is  a  short  structured  widely
used diagnostic interview, jointly developed by psychiatrists and clinicians in the United
States and Europe. It is validated for the diagnosis of DSM-IV and ICD-10 psychiatric
disorders (Sheehan et al. 1994, Sheehan et al. 1998).
2.1.1.4 Beck Depression Inventory
The Beck Depression Inventory (BDI) is probably the most commonly used self-rating scale
for depression. In the planning of the research design of a project aimed at testing certain
psychoanalytic formulations of depression, the necessity for establishing an appropriate
system for identifying depression was recognized (Beck et al. 1961). In its original version,
subjects were asked to rate 21 items (Table 3) according to how they feel at the present time.
Items were then scored from 0 to 3 and summed to obtain a total score for depressive
symptom severity (range from 0 to 63) (Beck et al. 1961, Beck and Beamesderfer 1974).
6Table 3. The symptom-attitude categories of the BDI (Beck et al. 1961)
a. Mood l. Social Withdrawal
b. Pessimism m. Indecisiveness
c. Sense of Failure n. Body Image
d. Lack of Satisfaction o. Work Inhibition
e. Guilty Feeling p. Sleep Disturbance
f. Sense of Punishment q. Fatigability
g. Self-Hate r. Loss of Appetite
h. Self-Accusations s. Weight Loss
i. Self-Punitive Wishes t. Somatic Preoccupation
j. Crying Spells u. Loss of Libido
k. Irritability
The  primary  clinical  use  of  the  BDI  is  to  assess  the  severity  of  depressive  symptoms  in
patients with previously diagnosed depressive illness. A second use of the BDI is to screen
subjects who may have depressive illness or may need intervention, but in this case it
should be  followed up with a  diagnostic  instrument  or  a  clinical  interview (Handbook of
Psychiatric Measures 2000).
The BDI has several advantages: it is easy and quick to use (self-administered), uses simple
language and is easy to score. A disadvantage is that biases have been reported (e.g.
women, the less-educated, adolescents, elderly people and individuals with certain
comorbid psychiatric diagnoses such as prominent anxiety tend to show higher scores)
(Handbook of Psychiatric Measures 2000).
2.1.1.5 Psychometric properties of the BDI
The term ‘psychometric’ is used to describe the performance characteristics of many types
of measures. The two principal psychometric properties of a measure are reliability and
validity.  The  reliability  of  a  test  is  the  consistency  or  precision  with  which  it  can
discriminate one subject from another, while the validity of a measure is the degree to
which the diagnosis, category, rating or score it yields is a reflection of the true state. When
evaluating  the  reliability  of  a  test,  internal  consistency  and  joint  and  test-retest  reliability
are assessed (Handbook of Psychiatric Measures 2000).
On  the  other  hand,  sensitivity  and  specificity  are  the  statistics  of  choice  when  a
measure’s ability to evaluate categorical variables such as diagnoses has to be assessed
(Hulley and Cummings 1988, Zarin and Earls 1993).
Sensitivity refers to a test’s ability to identify true cases, or its true positive rate.
Specificity is the test’s accuracy in identifying noncases, or one minus the false-positive
rate. The other key terms to take into account concerning a measure’s validity against a
gold standard are PPV (positive predictive value) and NPV (negative predictive value).
PPV is the probality (in a given population) that a positive test result corresponds to a true
case, and NPV is the probality (in a given population) that a negative test result
corresponds to a noncase (Handbook of Psychiatric Measures 2000).
The BDI shows high internal consistency among different study populations (Beck et al.
1988). Assessments of BDI test-retest reliability are problematic because repeated testing
7has often involved comparing questionnaires repeated outside the time frame mandated by
the first administration of the questionnaire. To assess the stability of one-week
assessments, repeated measurements must be carried out using the same unit of
observation  but  varying  the  time  of  administration  (e.g.,  morning  and  afternoon).  The
correlation between the BDI and other standard measures of depressive symptom severity
demonstrates high, but not complete, concordance across measures. Correlations between
observer-rated  scales  of  depression  such  as  the  HAM-D  or  MADRS  and  the  BDI  for
psychiatric patients range from 0.55 to 0.96, with a mean of 0.72. For nonpsychiatric
subjects, correlations range from 0.55 to 0.73, with a mean of 0.60 (Handbook of Psychiatric
Measures 2000).
Higher sensitivity scores have been reported in nonpatient populations. The BDI also
shows high concurrent validity with other measures of depressive symptom severity, such
as the Ham-D and the Zung SDS (Handbook of Psychiatric Measures 2000).
2.1.1.6 The BDI and screening of depression
Originally, Beck suggested that a cut-off point of 12/13 would be suitable to detect
depression among psychiatric patients, while 9/10 should be used among medical/non-
psychiatric patients (Beck et al. 1961). Two previous Finnish studies have suggested
different cut-off points: 14/15 in a clinical sample and 17/18 in a population-based but
geographically highly selected sample were found to maximize sensitivity and specificity in
detecting depression (Viinamäki et al. 2004, Nuevo et al. 2009). The optimal cut-off point of
the BDI seems to be dependent on the reference group and on the method applied to
confirm the diagnosis of depression. Therefore, a wide range of cut-off points (from 10 to
23) have been suggested in the literature (for a review, see Viinamäki et al. 2004). For
example, in a study among young adults (outpatient ages 18–37 years), a BDI cut-off score
of 18 was recommended for maximal efficiency (sensitivity 66.88%, specificity 58.90%)
(Rudd and Rajab 1995). On the other hand, the mean BDI score correlated well with the
prevalence of depression determined by clinical interviews (Veerman et al. 2009). A recent
study using the Composite International Diagnostic Interview as the gold standard reported
that the BDI might be useful in detecting depressive disorders in the general population
(Aalto et al. 2012).
The literature on the psychometric properties of the BDI in both clinical and non-clinical
samples/settings as well as across different countries is extensive. There have only been two
published studies examining the predictive value of the BDI for the detection of depression
in a representative sample of the general population that have applied a reliable psychiatric
interview as a validation instrument (Lasa et al. 2000, Nuevo et al. 2009). They suggested
different cut-off points in the BDI, 12/13 and 17/18 respectively, to obtain maximal
sensitivity and specificity.  The cut-off of 10 points in the BDI has been shown to be useful
for detecting depressive symptoms in various adult populations (Timonen et al. 2006,
Räikkönen et al. 2007, Vanhala et al. 2009, Koponen et al. 2010, Korniloff et al. 2010,
Mäntyselkä et al. 2011).
2.1.2. Subtypes of depression according to the DSM-IV
According  to  the  DSM-IV,  mood  episodes  and  mood  disorders  can  be  distinguished.  An
episode is a period lasting at least 2 weeks during which there are enough symptoms for
the full criteria to be met for the disorder. Furthermore, depressive disorders take one of
three forms: a major depressive episode, a dysthymic disorder or “depression not
otherwise specified”, which includes several forms of briefer or milder periods of
depression.
Patients with or without a history of mania may have a major depressive episode if they
fulfil these criteria, but major depressive disorder refers to one or more episodes of major
depression  in  the  absence  of  mania  or  hypomania.  Dysthymic  disorders  in  the  DSM-IV
8consist of chronic but milder symptoms than major depressive episode (American
Psychiatric Association (APA) 1994).
According  to  the  DSM-IV,  other  subtypes  of  depression  are  also  categorized,  for
example recurrent brief depressive disorder or seasonal pattern depressions (APA 1994,
Angst and Hochstrasser 1994, Partonen and Lönnqvist 1999,Westrin and Lam 2007).
2.1.2.1. The prevalence of major depressive episode or depressive disorders
Numerous studies have shown that major depression is a common disorder in the general
population (Ayoso-Mateos et al. 2001, Kessler et al. 1994, Kessler et al. 2003). It frequently
has  a  recurrent  or  chronic  course,  significantly  impairing  the  quality  of  life  and  being
among the most important causes of the disease burden and years lost due to disability
(Murray et al. 1996). In the Finnish population, the 12-month prevalence of major
depressive episode was 9.3% (Lindeman et al. 2000). Depressive disorders were found in
6.5% of the subjects in the Finnish Health 2000 Study (Pirkola et al. 2005). An even higher
rate has been reported in primary care, as the 12-month prevalence of clinical depression
was 20% (Salokangas et al. 1996). The lifetime prevalence of depressive disorders was
almost 18% in the latest Finnish study among the younger population (Suvisaari et al. 2009).
Published prevalence rates may vary due to differences in samples and methods applied.
Controversial results have been published when evaluating the differences in depression
prevalence over time. A study using identical diagnostic criteria at both time points
reported an increase of over two-fold in the 12-month prevalence of depression during a 10-
year period (Compton et al. 2006). However, subsequent reports have failed to confirm the
often publicly presented hypothesis that depression is more common at present
(Hawthorne et al. 2008, Patten 2008).
On the other hand, 11–21% of persons in Finland have an elevated number of depressive
symptoms (DS) assessed according to the Beck Depression Inventory (BDI ³ 10 points)
(Vaananen et al. 2008, Vanhala et al. 2009).
2.1.2.2. Diagnosis and symptoms of major depressive episode
Major depression is clinically the most important entity among the spectrum of depressive
disorders. Besides defining the traditional major depressive episode, it can be typed by the
presence of the most prominent symptoms, such as the melancholic or atypical features.
The fourth edition of Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)
published in 1994, and the text revision in 2000, is the latest and most up-to-date
classification of mental disorders (APA 1994, APA 2000). The fourth edition correlates with
the 10th revision of the World Health Organisation’s International Classification of Diseases
and Related Health Problems (ICD-10) (WHO 1992). A definition of a major depressive
episode is provided in Table 4.
9Table 4. DSM-IV criteria for a major depressive episode (American Psychiatric Association 1994)
A. Five (or more) of the following symptoms have been present during the same 2-week period
and represent a change from previous functioning; at least one of the symptoms is (1)
depressed mood or (2) a loss of interest or pleasure:
(1) depressed mood most of the day, nearly every day, as indicated by either subjective
report or observation by others
(2) markedly dimished interest or pleasure in all, or almost all, activities most of the
day, nearly every day (as indicated by either subjective account or observation by
others)
(3) significant weight loss when not dieting or weight gain (e.g., a change of more than
5% of body weight in a month), or an increase in appetite nearly every day
(4) insomnia or hypersomnia nearly every day
(5) psychomotor agitation or retardation nearly every day (observable by others, not
merely subjective feelings of restlessness or being slowed down)
(6) fatigue or loss of energy nearly every day
(7) feelings of worthlessness or excessive or inappropriate guilt (which may be
delusional) nearly every day (not merely self-reproach or guilt about being sick)
(8) a diminished ability to think or concentrate, or in decisiveness, nearly every day
(either subjective account or as observed by others)
(9) recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation
without a specific plan, or a suicide attempt or a specific plan for committing suicide
B. The symptoms do not meet the criteria for a mixed episode
C. The symptoms cause clinically significant distress or impairment in social, occupational, or
other important areas of functioning
D. The symptoms are not due to the direct physiological effects of a substance or a general
medical condition
E. The symptoms are not better accounted for by bereavement, i.e., after the loss of a loved one,
the symptoms persist for longer than 2 months or are characterized by marked functional
impairment, morbid preoccupation with worthlessness, suicidal ideation, psychotic
symptoms, or psychomotor retardation
2.1.2.3. Melancholic depression
In contrast to reactive depression, melancholic depression, as also referred to as
endogenous depression in the German literature, is characterised by greater severity, more
considerable guilt and loss of interest, typical vegetative symptoms such as decreased
appetite and sleep, and other physical symptoms such as difficulty concentrating, early
morning  awakening,  and  a  diurnal  mood  swing  (depression  is  worse  in  the  morning)
(Tsuang and Faraone 1996). Melancholic depression has a lower rate of response to
psychotherapy  and  placebo  when  compared  to  reactive  depression  (Tsuang  and  Faraone
1996).
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The DSM-IV defines a major depressive episode with melancholic features in a manner that
covers most of the features of endogenous depression (Table 5).
Table 5. The DSM-IV melancholic features specifier (American Psychiatric Association 1994)With
melancholic features (can be applied to the current or most recent major depressive episode in major
depressive disorder and to a major depressive episode in bipolar I or bipolar II disorder only if it is the
most recent type of mood episode)
A. Either of the following, occurring during the most severe period of the current episode:
(1) loss of pleasure in all, or almost all, activities
(2) lack of reactivity to usually pleasurable stimuli (does not feel much better, even
temporarily, when something good happens)
B. Three (or more) of the following:
(1) distinct quality of depressed mood (i.e., the depressed mood is experienced as
distinctly different from the kind of feeling experienced after the death of a loved
one)
(2) depression regularly worse in the morning
(3) early morning awakening (at least 2 hours before usual time of awakening)
(4) marked psychomotor retardation or agitation
(5) significant anorexia or weight loss
(6) excessive or inappropriate guilt
2.1.2.4 Atypical depression
Atypical depression is distinguished by mood reactivity (i.e., the capacity to be cheered up
temporarily by positive experiences or events) as well as by severe fatigue (so-called leaden
paralysis),  sensitivity  to  rejection,  self-pity,  a  reverse  diurnal  mood  swing  (depression  is
worse later in the day), and reverse vegetative symptoms (e.g., increased instead of
decreased appetite and sleep (Stung and Forgone 1996). About 15% of depressive episodes
have atypical features. Atypical depression has traditionally had a better response to
monoamine oxidase inhibitor antidepressants than to other antidepressants (Textbook of
Psychiatry 2005). However, antidepressive medication of this particular mechanism of
action is very seldom used in the treatment of depression in Finland. A major depressive
episode with atypical features is defined by the DSM-IV (Table 6).
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Table 6. DSM-IV atypical features specifier (American Psychiatric Association 1994)
With atypical features (can be applied when these features predominate during the most recent 2 weeks of a
major depressive episode in major depressive disorder or in bipolar I or bipolar II disorder when the major
depressive episode is the most recent type of mood episode, or when these features predominate during the
most recent 2 years of dysthymic disorder)
A. Mood reactivity (i.e., mood improves in response to actual or potential positive events
B. Two (or more) of the following features:
(1) significant weight gain or increase in appetite
(2) hypersomnia
(3) leaden paralysis (i.e., heavy, leaden feelings in arms or legs)
(4) long-standing pattern of interpersonal rejection sensitivity (not limited to episodes of
mood disturbance) that results in significant social or occupational impairment
C. Criteria are not met with melancholic features or catatonic features during the same
episode.
2.2.2.5. Other proposed subtypes of depression
Besides those mentioned above, some other subtypes of depression have also been
proposed, such as non-melancholic depression, metabolic depression and vascular
depression, that are not included in the DSM-IV.
Compared to melancholic depression, non-melancholic depression can be defined as a
major depressive episode not having the DSM-IV-based melancholic symptoms included in
the definition of melancholic depression (Rush and Weissenburger 1994, Whithall et al.
2010).
The definition of metabolic depression is based on the connection between the MetS and
depression (Vogelganzs et al. 2011). Depressed patients with the MetS are reported to be
more likely to have persistent or recurrent depression. The latter may suggest that
depression with metabolic abnormalities, which could be labelled as metabolic depression,
identifies a chronic subtype of depression (Vogelganzs et al. 2011).
The concept of vascular depression has also been presented. The vascular depression
hypothesis was proposed as a subtype of depression late in life (Alexopoulos et al. 1997,
Steffens et al. 1998, Hickie et al. 1995, Krishnan et al. 1995). During the history of the
vascular depression hypothesis, several researchers have proposed different diagnostic
criteria (Alexopoulos et al. 1997, Steffens et al. 1998, Krishnan et al. 2004, Alexopoulos et al.
2001, Sneed and Culang-Reinlieb 2011). Chronic inflammation may also underlie many
forms of depression associated with vascular disease and the metabolic syndrome
(Viscogliosi et al. 2011). Finally, to make progress regarding the validity of vascular
depression as a subtype of depression, its longitudinal course needs to be chararacterized
(Sneed et al. 2008).
2.2 The metabolic syndrome (MetS), proinflammation and depression
2.2.1 MetS and depression
2.2.1.1 Definitions and prevalence of the MetS
The metabolic syndrome (MetS) is a cardiometabolic risk cluster comprising abdominal
obesity,  altered  glucose  and  lipid  metabolism  and  elevated  blood  pressure  (Expert  panel
2001, Alberti et al. 2005, Grundy et al. 2005, Alberti et al. 2006). It is associated with an
increased risk of cardiovascular diseases, type 2 diabetes mellitus and all-cause mortality
(Lakka et al. 2002, Ford 2005). Although generally recognized, there has not been a uniform
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definition or diagnostic criteria for the MetS. The World Health Organization (WHO)
proposed the first commonly accepted criteria for the MetS in 1998: insulin resistance and
hyperinsulinemia are the core of the syndrome, as well as central obesity. In addition,
dyslipidemia, elevated blood pressure and glucose intolerance are included (World Health
Organisation 1999). The National Cholesterol Education Program (NCEP) – Adult
Treatment Panel III established a set of criteria for the MetS in 2001 (Expert panel on
detection, evaluation, and treatment of high blood cholesterol in adults 2001). Later, the
modified National Cholesterol Education Program (NCEP-ATPIII) introduced a lower
criterion of 5.6 mmol/l (100 mg/dL) for the fasting serum glucose cut-off point (Grundy et
al. 2005).
Since then, an internationally accepted definition for the MetS has been proposed by the
International Diabetes Federation (IDF) (The IDF consensus worldwide definition of the
metabolic syndrome 2006). The latest proposition to harmonize the criteria for the MetS
was published by the IDF and the American Heart Association (AHA) (Alberti et al. 2009).
When applying the NCEP criteria, the age-adjusted prevalence of the MetS is estimated to
be approximately 35% in the US population and 37% in Eastern Finland (Ford 2005,
Miettola 2008). Research into the mechanisms involved in the MetS is of great importance
due to the increasing occurrence of obesity and the growing prevalence of MetS.
Criteria for the metabolic syndrome according to NCEP, NCEP-modified, IDF and IDF/AHA
definitions are presented in Table 7.
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Table 7. Criteria for the metabolic syndrome according to NCEP, NCEP-modified, IDF and IDF/AHA definitions.
NCEP ATP III (2001) NCEP modified
(2005)
IDF (2005) IDF/AHA(2009)
Number of criteria
needed for diagnosis
Three or more of the
following
Three or more of the
following
The first plus any two
of the following
Three or more of
the following
Waist circumference
(males)
>102 cm >102 cm >94 cm Population- and
country-specific
definitions
Waist circumference
(females)
>88 cm >88 cm >80 cm Population- and
country-specific
definitions
Hypertension BP ³130/85 mmHg or
specific medication
BP ³130/85 mmHg or
specific medication
BP ³130/85 mmHg or
specific medication
Systolic ³130
and/or diastolic
³85 mmHg or
specific medication
Trigycerides ³150 mg/dL or ³1.7
mmol/L or specific
medication
³150 mg/dL or ³1.7
mmol/L or specific
medication
³150 mg/dL or ³1.7
mmol/L or specific
medication
³150 mg/dL or ³1.7
mmol/L or specific
medication
HDL cholesterol (men) <40 mg/dL or <1.03
mmol/L or specific
medication
<40 mg/dL or <1.03
mmol/L or specific
medication
<40 mg/dL or <1.03
mmol/L or specific
medication
<40 mg/dL or <1.0
mmol/L or specific
medication
HDL cholesterol
(women)
<50 mg/dL or <1.29
mmol/L or specific
medication
<50 mg/dL or <1.29
mmol/L or specific
medication
<50 mg/dL or <1.29
mmol/L or specific
medication
<50 mg/dL or <1.3
mmol/L or specific
medication
Fasting plasma glucose ³110 mg/dL or ³6.1
mmol/L or specific
medication
³100 mg/dL or ³5.6
mmol/L or specific
medication
³100 mg/dL or ³5.6
mmol/L or specific
medication
³100 mg/dL or ³5.6
mmol/L or specific
medication
AHA = American Heart Association
ATP = Adult Treatment Panel
BP = blood pressure
HDL = high-density lipoprotein
IDF = International Diabetes Federation
NCEP = National Cholesterol Education Programme
2.2.1.2 Association between the MetS and depression
Most previous cross-sectional studies have demonstrated that the MetS is more common in
depressed than in  non-depressed subjects,  and the  observed prevalence  rates  have varied
from 8% to 38% (Kinder et al. 2004, Heiskanen et al. 2006, Räikkönen et al. 2007, Skilton et
al. 2007). In a recent study by East et al. (2010), women and men who exhibited depressive
symptoms had a higher prevalence of the MetS compared to those who did not (15.4%
versus 7.2% for women; 31.6% versus 22.8% for men). In a study by Laudisio and
coworkers, the MetS was independently associated with depressive symptoms in
community-dwelling elderly women, but not in men (Laudisio et al. 2009). In a 15-year
follow-up study, depressive symptoms and stressful life events at baseline were predictive
of the metabolic syndrome in a sample of females (Räikkönen et al. 2007). Psychological
distress may also increase the risk of later MetS (Puustinen et al. 2010).
On the other hand, a two-way connection may exist between depression or DS and the
MetS (Pan et al. 2012). The MetS predisposed to DS in a population-based 7-year follow-up
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(Koponen et al. 2008). Another longitudinal 6-year follow-up study examined the same
phenomena. In that study, at baseline, 235 out of 823 persons had metabolic syndrome and
168 were depressed (CES-D score ? 20). Among those not depressed at baseline, 26.0%
developed depression. A higher waist circumference increased the odds of depression
onset, but there was no association between other metabolic syndrome components or the
MetS and the onset of depression. Among persons depressed at baseline, depression had a
chronic character in 69.0% of those without and 88.5% of those with the metabolic
syndrome. The chronicity of depression was defined by a CES-D score ³20 both at baseline
and after 3 or 6 years. Metabolic syndrome was associated with an almost 3-fold increase in
the odds of chronicity of depression (Vogelganzs et al. 2011).
The association between depression and the MetS may not, however, be unequivocal, as
the largest published cross-sectional study to date (n = 9571) detected no association
between depression or anxiety and the MetS (Hildrum et al. 2009). Another large study also
revealed no association between a lifetime history of major depression and the presence of
the MetS (Foley et al. 2010).
Depression may be a risk factor for several components of the MetS. A tendency
towards dyslipidemias and visceral fat accumulation is also associated with depression
(Weber-Hamann et al. 2006). In a study by Richter et al. (2010), a correlation between
triglyceride levels and the severity of depression was observed in both the acute stage as
well as in remission in a group of acutely depressed in-patients with the MetS. Depression
in women, but not in men, was associated with a two-fold higher risk of having the MetS
(Toker et al. 2008). In both men and women, depression was associated with an increased
waist circumference (Toker et al. 2008). In addition, low HDL cholesterol associated with
major depression in a sample with a 7-year history of DS (Lehto et al. 2008).
2.2.1.3 The MetS and subtypes of depression
A recent study categorized depression into a severe melancholic depressive class, a severe
atypical depressive class and a depressive class of moderate severity. The atypical class
showed more MetS than the melancholic class (Lamers et al. 2010). A higher prevalence of
abdominal obesity and hypertriglyceridemia was also identified among subjects in the
severe atypical depressive class than in the severe melancholic class (Lamers et al., 2010).
Furthermore, melancholic features were independently associated with lower HDL
cholesterol, and atypical depression was independently associated with higher total and
LDL cholesterol (van Reedt Dortland et al. 2010). Another study by Luppino and coworkers
demonstrated a strong association of waist circumference, triglyceride levels and blood
pressure with the somatic arousal symptom dimension assessed by the Mood and Anxiety
Symptom Questionnaire (Luppino et al. 2011). In a recent study, women with
undifferentiated and atypical features of major depressive disorder exhibited a greater BMI
and higher whole body and abdominal fat mass compared to healthy controls (Cizza et al.
2012). The MetS may be also associated with seasonal changes in mood and weight
(Rintamäki et al. 2008).
The only longitudinal study reporting the risk of metabolic syndrome in various
subtypes of DS has been the subgroup analysis of Vanhala and co-workers. Females with
DS at baseline, compared to those without DS, were shown to have a 2.5-fold higher risk of
the MetS at the end of the 7-year follow-up The risk was highest in the subgroup with more
melancholic  symptoms.  Among  men  there  was  no  risk  difference,  and  males  had  less
severe DS than females, suggesting that the severity of DS may affect the prevalence of the
MetS in DS (Vanhala et al. 2009). These findings suggest that the association between
depression and the MetS may only be present in certain subtypes of depression.
2.2.1.4. Proposed mediating pathways between the MetS and depression
Underlying mechanisms that may explain the association between depression and the MetS
include genetic factors (Zeman et al. 2009), low-grade inflammation and increased secretion
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of proinflammatory cytokines (Ovaskainen et al. 2009, Zeugmann et al. 2010). In addition,
dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis resulting in inappropriate
cortisol secretion (Bjorntop 2001, Muhtz et al. 2009, Vogelzangs et al. 2009) may play a role.
An imbalance in autonomous neurotransmission may also contribute to persistent
(over)activation of the autonomic nervous system, which could lead to metabolic
alterations, but the underlying mechanisms are complex and not clearly understood
(Tentolouris et al. 2008). Decreased parasympathetic nervous system activity and increased
sympathetic nervous system activity were associated with the Mets and its components
when the interbeat interval time, pre-ejection period and respiratory sinus arrhythmia were
applied to reflect autonomous nervous system activity (Licht et al. 2010).
Leptin resistance may also contribute (Zeman et al., 2009). Leptin regulates dietary intake
and appetite by acting on leptin receptors in the brain, particularly the hypothalamus
(Brennan and Mantzoros 2006).
2.2.2. The role of proinflammation
2.2.2.1 Proinflammation and depression
The  literature  on  cytokines  and  depression  is  abundant,  and  a  large  amount  of  evidence
indicates that depressed patients exhibit increased levels of markers of innate immune
system activation and inflammation (Miller et al. 2009, Raison and Miller 2011). In a meta-
analysis of over 50 studies, the majority of studies reported depressed patients to have
elevations in the proinflammatory cytokines interleukin (IL)-6, and IL-1 beta, as well as an
acute phase protein, C-reactive protein (CRP) (Howren et al. 2009). While both positive and
negative results have been reported in individual studies, a recent meta-analysis indicated
that  depression  may  be  accompanied  by  activation  of  the  inflammatory  response  system
(Dowlati et al. 2010). According to Dowlati et al. (2010) and Maes (2011), major depression
is characterized by an inflammatory response, such as with increased production of
cytokines interleukin-6 and tumour necrosis factor-alpha. Besides this, Maes emphasized
the role of cell-mediated immune activation that involves cellular interactions between T
lymphocytes and monocytes, which is manifested by T cell activation in depression and
may lead to serotonergic disturbances (Maes 2011). Thus, the lowered availability of
plasma L-tryptophan (the precursor of serotonin) in the brain in depression is a marker of
immune activation, indicating that lowered plasma L-tryptophan, and hence serotonin, are
induced through the activation of indoleamine 2,3-dioxygenase (IDO) (Maes 2011). In this
way, serotonin can play a role in the inflammatory system response in major depression
(Song et al. 1998). Cell-mediated immune activation can also cause glucocorticoid resistance
in immune cells, suggesting that HPA hyperactivity in depression is induced by pro-
inflammatory cytokines (Maes 2011). Incongruent results nevertheless exist, since
circulating cytokine concentrations were not associated with major depressive disorder in a
community-based cohort in a recent study (Einvik et al. 2012). Cytokines may affect not
only central monoamine synthesis, release and reuptake, but also neuroendocrine function
and neural plasticity (Miller et al. 2009). Moreover, long-term exposure to cytokines may
lead to depressive disorders. For example, 20% to 50% of patients receiving chronic
interferon alpha therapy for the treatment of infectious diseases or cancer developed
clinically significant depression (Musselmann et al. 2001, Capuron et al. 2002). A recent
longitudinal study reported a correlation between the capacity of T-cells and monocytes to
produce cytokines and the development of DS in response to a period of severe stress (van
Zuiden et al. 2011).
2.2.2.2 Proinflammation and subtypes of depression
Research data on the association between inflammation and different subtypes of
depression  are  scarce.  A  study  by  Kaestner  and  coworkers  reported  higher
proinflammatory cytokines levels in patients with non-melancholic major depression,
whereas in patients with melancholic depression the levels did not differ from the controls
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(Kaestner et al. 2005). In the follow-up, the levels were normalized with remission. The
incidence of immunoglobulin G/immunoglobulin M-mediated autoimmune responses
directed against serotonin is significantly higher in depression, particularly in melancholia.
Thus, autoimmune reactions against serotonin may play a role in the pathophysiology of
depression and the onset of severe depression. These data may provide support for the
notion that melancholia could be a valid subtype of depression (Maes et al. 2012).
2.2.2.3 Proinflammation and the MetS
The link between inflammation and depression may explain the frequent connection
between medical illnesses and depression (Benton et al. 2007). While several medical
conditions are associated with increased rates of depression, the majority of these illnesses
are also linked with increased inflammation, including not only autoimmune and
infectious diseases and cancer but also cardiovascular disease and diabetes, both of which
are recognized to have an inflammatory component (Hevener and Febbraio 2010).
Inflammation and the induction of oxidative and nitrosative stress (IO&NS) are connected
with depression and may provide one possible explanation for the association between
depression and various disorders such as the MetS, obesity and diabetes (Ames et al. 2011).
Inflammation is not only a triggering factor of the MetS but also a consequence:
inflammatory cytokines are produced by fat cells, and resistance to the anti-inflammatory
effects of insulin may cause increased cytokine levels (Esposito and Giuliani 2004).
Furthermore, metabolically healthy obese older persons were found to have a more
favourable fat distribution and inflammatory profile compared with their metabolically
unhealthy obese counterparts (Koster et al. 2010). In addition, non-obese and obese
individuals who develop an intense pro-inflammatory state may be more prone to
developing the MetS than those with lower levels of inflammation (Stenholm et al. 2010).
2.2.2.4 Proinflammation, diet and the role of white adipose tissue (WAT)
Dietary excess may promote a general proinflammatory state, which could contribute to
metabolic disturbances and diseases such as dyslipidemias, cardiovascular disease, and
type 2 diabetes (Shelton and Miller 2010, Shelton and Miller 2011, Shoelson et al. 2007, Bays
et al. 2008, Gustafson 2010).
Diet may also contribute to metabolic dysregulatios, since a high intake of fructose
contributes to problems with obesity and metabolic diseases such as cardiovascular
disease, dyslipidemia and type 2 diabetes (Tappy and Le 2010, Angelopoulos et al. 2009).
High fructose loading in the liver leads to the synthesis of triglycerides, which may cause
the accumulation of liver and abdominal fat (Stanhope et al. 2008). The so-called white
adipose tissue (WAT) is the main location for long-term fat storage in the human body, and
may have a role in metabolic disturbances (Mathieu et al. 2009). WAT, particularly in the
abdomen, is the main contributor to metabolic diseases (Calabro and Yeh 2008, Despres et
al. 2008). The adipocytes in WAT are capable of secreting cytokines and chemokines  (Carr
et al. 1994, Xu et al. 1996, Tilg and Moschen 2006). Thus, WAT may contribute to
widespread immune activation, potentially causing or exacerbating diseases linked with
inflammation such as type 2 diabetes, cardiovascular diseases, cancer, and depression (Tilg
and Moschen 2006).
Elevated homocysteine levels, mainly caused by a deficiency in folate or vitamin B12
levels, may have associations with inflammatory parameters (Gori et al. 2005, Mabrouka et
al. 2010).
2.4 Diet and depression
2.4.1 Quality of diet and depression
Most research on the association between the diet and depression or DS has focused on
different type of diets, and the main interest has been in the impact of fish oils, dietary fish,
omega- 3 fatty acids, folate, vitamin B12 and obesity.
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The so-called Mediterranean Diet Pattern (MDP) has been reported to associate with a
reduced risk of depression (Tortosa et al. 2007, Sanchez-Villegas et al. 2009). Due to the
current epidemic of obesity, so-called very low carbohydrate (LC) diets that are typically
high in protein and fat (particularly saturated fat) have been introduced, and they can be an
effective alternative dietary approach for those intending to lose weight (Astrup et al. 2004,
Stern et al. 2004, Dansinger et al. 2005). No clear effect on mood has been found in short-
term studies  with  a  very low carbohydrate  (LC)  or  a  low fat,  high carbohydrate  diet  (LF)
when they have been compared with each other (Kogon et al. 1994, Rosen et al. 1982,
D’Anci et al. 2009). On the other hand, one study has reported similar improvements in the
mood state in overweight obese women with both LC and LF diets (Halyburton et al. 2007).
The long-term effects of an LC diet on mood have been poorly studied. Only one
randomized, controlled study has compared the effects a moderate energy-restricted LC
diet with those of a conventional isocaloric LF diet over a one-year period. Both diets had
positive effects on weight loss,  but the LF diet had a more favourable effect on the mood
state compared with the LC diet (Grinkworth et al. 2009). The sustained improvement in
the LF group is consistent with the findings of epidemiological studies showing that diets
high in carbohydrates and low in fat and protein are associated with lower levels of anxiety
and depression and have beneficial effects psychological well being (Pellegrin et al. 1998,
Munoz et al. 2009).
2.4.2 Sources and deficiency of folate and vitamin B12
Folate is a group of water-soluble naturally occurring compounds mostly found in green
vegetables, peanuts, legumes and wholegrain bread, but also in milk products and fruits
(Chanarin 1979, The National Nutrition Council 2005). In Finland and in the USA, the
recommended daily allowance for folate is 300 µg/day and 400µg/day, respectively (The
National Nutrition Council 2005, Food and Nutrition Board, Institute of Medicine 1998).
The prevalence of a low plasma folate concentration was 10% among the Finnish
population aged 25–74 years, and in Eastern Finland only 25% of middle-aged men had the
recommended daily allowance for folate (Alfthan et al. 2002, Tolmunen et al. 2003). There
has been a large reduction in the prevalence of folate deficiency in the general population
due to folic acid fortification of the food supply in Canada (De Wals et al. 2007). On the
other hand, among persons aged 65–74 and ³75 years, approximately 10% and 20%,
respectively, were at high risk of folate deficiency in Great Britain (Clarke et al. 2003).
Folate deficiency causes macrocytic anemia and congenital neural tube deficits, as well
as  neuropsychiatric  symptoms  similar  to  vitamin  B12 deficiency (Lindenbaum and Allen
1995, Reynolds 2006).
Vitamin B12 is only synthesized by bacteria,  for which reason its only source is food of
animal  origin,  e.g.  meat,  fish,  eggs  and  milk  products  (Allen  and  Dror  2011).  The
prevalence  of  vitamin  B12 deficiency was reported to be 12% in the Finnish population
(aged 65–100 years), whereas 5% of Canadians (aged 6–79 years) were vitamin B12 deficient
(Loikas et al. 2007, Mac Farlane et al. 2011). Lifestyle factors such as smoking, alcohol
consumption and a vegetarian diet have been linked with an increased risk of vitamin B12
deficiency in younger adults (Herrmann and Geisel 2002, Wolters et al. 2004), but no such
association was recorded in an aged Finnish population (Loikas et al. 2007).  No specific
risk group for lower vitamin B12 levels could be defined among the aged, but aging itself
increases the probability of vitamin B12 deficiency (Loikas et al. 2007). The clinical
presentation of vitamin B12 deficiency varies considerably and rarely includes all the classic
features, such as macrocytic anaemia, peripheral neuropathy, and subacute combined
degeneration of the spinal cord. More typically, vitamin B12 deficiency presents as
nonspecific symptoms of fatigue, lassitude, vertigo and cognitive impairment that could be
attributed to old age (Stabler 2000).
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Furthermore, an association between depression and low folate or vitamin B12 levels has
even been reported in the normal range of these vitamins (Coppen and Bailey 2000,
Hintikka et al. 2003).
2.4.3 Evaluation of folate intake
The  food  frequency  questionnaire  (FFQ)  is  currently  the  main  method  for  estimating  the
role of the diet in the aetiology of chronic diseases. The popularity of the FFQ is based on
its feasibility and low cost compared to other methods, and it describes the habitual diet,
which is often more relevant to the study hypothesis than the current, short-term diet
(Willett 1990). The FFQ includes 132 food items, which are recorded by applying nine
possible frequency categories. The collected food data are subsequently converted into
nutrients by specific computer software. It is also a well-validated method for estimating
the dietary folate intake (Männistö et al. 1996, Paalanen et al. 2006, Kaartinen et al. 2011).
2.4.4 Association between folate intake and depression
Most studies examining the association between folate and depressive symptoms (DS) have
been based upon serum folate levels. Many cross-sectional studies have demonstrated that
low levels of folate are associated with the risk of depression or elevated depressive
symptoms in adults (Lee et al. 1998, Tiemeier et al. 2002, Sanchez-Villegas et al. 2009,
Beydoun  et  al.  2010,  a,  b),  which  has  been  supported  in  a  longitudinal  study  in  an  older
Korean population (Kim et al. 2008). However, the findings have not been consistent, since
no association between folate levels and DS was detected in a longitudinal study among
young women registered in general practices in England (Kendrick et al. 2008). In addition,
the associations between depressive symptoms or depression and folate levels may be
confounded by different subtypes of DS, as in a clinical study in which subjects with low
folate levels were more likely to have melancholic depression (Fava et al. 1997).
Research data on the relationship between folate intake and depression are scarce, since
only a few cross-sectional studies have reported an association between folate intake and
DS or depression (Tolmunen et al. 2003, Sanchez-Villegas et al. 2009, Murakami et al. 2010).
Of the three published prospective studies, two reported an increased risk of depression
or recurrent depression in men with a low folate intake (Tolmunen et al. 2004, Astorg et al.
2008). Contradictory results exist, as a recent U.S. population-based study reported that the
intake of folate was not associated with DS (Skarupski et al. 2010).
2.4.5 Evaluation of vitamin B12 levels
Vitamin B12 was technically difficult to measure until the introduction automated, reliable
assays (Carmel 2002, Robinson et al. 2010). Despite the advance in assay techniques, relying
on vitamin B12 measurement alone remains problematic, since most measured vitamin B12 is
bound to transporter proteins and is not bioavailable. Moreover, the clinical severity of
vitamin  B12 deficiency is unrelated to vitamin B12 concentrations (Carmel 2000, Stabler
2000). Only that portion bound to the delivery protein holotranscobalamin, i.e. 20%, is
available to end tissues (Carmel 2002). Measurement of this protein is considered a more
accurate tool of recent vitamin B12 absorption, and a better approximation of end-tissue B12
repletion (Bor et al. 2004).
2.4.6 Association between vitamin B12 levels and depression
In  clinical  studies,  lower  vitamin  B12 levels have been found to be associated with severe
depression (Bell et al. 2001, Mischoulon et al. 2000) or with DS (Robinson et al. 2011). On
the other hand, high vitamin B12 levels were associated with a good treatment outcome in
patients with major depressive disorders in a clinical setting (Hintikka et al. 2003).
However, a small randomized trial found no improvement in depression after the
administration of vitamin B12 as an adjuvant (Hvas et al. 2004). A recent study reported no
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clear potentiation of the effect of antidepressant medication on DS by folate and vitamin B12
supplementation (Christensen et al. 2011).
Three cross-sectional studies have reported an association between vitamin B12 levels
and depressive disorders (Penninx et al. 2000, Tiemeier et al. 2002, Ng et al. 2009). The only
existing community-based prospective study reported that lower levels of vitamin B12 at
baseline were associated with a higher risk of incident depression on 2- to 3-year follow-up
among older Korean people (Kim et al. 2008). However, previous results have been
somewhat inconsistent, since some studies have found no association between vitamin B12
levels and DS or depressive disorders (Lindeman R et al. 2000, Morris et al. 2003, Bjelland et
al. 2003, Sachdev et al. 2004, Beydoun et al. 2010).
2.4.7. Proposed mediating pathways between folate, vitamin B12 and depression
A wide array of aetiological hypotheses has been suggested to explain depression. Of the
biological hypotheses, the monoamine hypothesis proposes an important aetiological role
for serotoninergic or noradrenergic dysfunction in depression (Stahl 2008). Folate and
vitamin  B12 are  involved  in  single-carbon  transfer  reactions  needed  for  the  production  of
serotonin and other monoamine neurotransmitters (Coppen et al. 1989). Folate and vitamin
B12 deficiency may also result in the accumulation of homocysteine, which has been
suggested to lead to exitotoxic reactions and may enhance depression (Stabler et al. 1990,
Parnetti et al. 1997). Homocysteine can be remethylated to methionine, which requires
vitamin  B12 (Bottiglieri 2005). Methionine is the immediate precursor of S-
adenosylmethionine (SAM), the methyl donor of numerous methylation reactions in the
brain, many of which are directly involved in the synthesis and metabolism of dopamine,
norepinephrine and serotonin (Bottiglieri et al. 2000, Coppen and Bolander-Gouaille 2005).
It has even been suggested that a specific subtype of depression may exist with high total
plasma homocysteine levels due to low methylation in the central nervous system caused
by folate deficiency (Bottiglieri 2000). On the other hand, alternative views of homocysteine
include its role as a chemoattractant in tissue damage and inflammation (Dudman 1999).
Methyl donation is required for subsequent monoamine neurotransmitter formation: while
some empirical evidence for this exists, it is of poor quality (Williams et al. 2005). These
findings form a plausible link between folate, vitamin B12 and mood, and may also indicate
that the association between depression and folate or vitamin B12 could be mediated
through monoamine synthesis.
In addition to its role in the one-carbon cycle, vitamin B12 could  play  a  role  in  the
methylmalonic acid pathway, and its deficiency leads to a rise in the levels of
methylmalonic acid. Depressed subjects have been reported to have higher methylmalonic
acid levels (Penninx et al. 2000).
Vascular depression is also a possible mediating pathway between folate, vitamin B12
and depression or DS. Alexopoulos proposed an operational description of “vascular
depression” in 1997, and radiological findings of subcortical ischemic depression were
reported in the same year (Alexopoulos et al. 1997, Krishnan et al. 1997). Although some
evidence does not support an association between the cortical vascular disease burden and
depressive symptoms, the concept is considered reasonably robust (Baldwin 2005). It is also
posited that a deficiency of folate or vitamin B12 could cause elevated homocysteine levels,
thereby increasing atherosclerosis, hence causing vascular depression (Folstein et al. 2007).
Moreover, vitamin B12 deficiency has been associated with a greater burden of vascular
lesions on neuroimaging (De Lau et al. 2009).
20
3 AIMS OF THE STUDY
This study was undertaken to investigate the association between predominantly
melancholic or non-melancholic DS, measured by the BDI, and the MetS, folate intake and
serum vitamin B12 levels in a population-based study.
The specific aims were:
1.  To  evaluate  the  value  of  the  BDI  as  a  screening  instrument  for  depression  and  the
depressive symptom profile using the clinical DSM-IV-based Mini-International Psychiatric
Interview (MINI) as a validating measure among middle-aged and elderly subjects living in
different geographical regions.
2. To examine the prevalence of the MetS and its components in groups with
predominantly melancholic or non-melancholic DS.
3.  To  study  the  association  between  folate  intake  and  DS  in  groups  with  predominantly
melancholic or non-melancholic characteristics.
4. To assess the correlation between vitamin B12 levels and DS in groups with melancholic
or non-melancholic features divided according to the BDI.
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4 SUBJECTS AND METHODS
4.1 Subjects
The study population was enrolled as a part of the national type 2 diabetes prevention
programme (FIN-D2D), as a project of the Finnish community-based type 2 diabetes
prevention programme, aimed at exploring the ways to implement these preventive
methods for type 2 diabetes on a national level. Three hospital districts of Finland, namely
Pirkanmaa,  Southern  Ostrobothnia  and  Central  Finland,  were  selected  for  the  efficacy
survey, which was carried out between October and December 2007 (Saaristo et al. 2007). A
representative random sample of 4500 subjects aged 45–74 years, stratified according to
gender, 10-year age groups (45–54, 55–64 and 65–74 years) and the three geographical
areas, was selected from the National Population Register in August 2007. Of the 4500
persons who were invited by mail to the health examination, 2868 participated (attendance
64%). The participants (N = 2868) and the nonparticipants (N = 1632) did not differ with
regard to gender or age.
The Ethics Committee of the Hospital District of Helsinki and Uusimaa granted ethical
permission  for  the  study.  All  participants  provided  written  informed  consent  prior  to
participation in the study.
Figure 1 presents a flow chart of studies I–IV. In study I, 432 subjects had a BDI score of
10 points or more, and the MINI was performed on 162 participants out of 432. Of the
original population (N = 2868), 48 participants were excluded from the analyses because of
incomplete data for the MetS (study II). Similarly, 62 subjects with missing data for folate
intake (study III) and the same number of participants without vitamin B12 levels  were
exluded (study IV).
Random sample of 4500 subjects
-10-years agegroups: 45-74
2868 participated
- Attendance 64%
Study 1
N=432
-Beck 10+: N=432
- M.I.N.I: N=162
Study 2
N=2820
-Beck 10+: N=432
- MetS+: N=1503
Study 3
N=2806
Folate: N=2806
-Beck 10+: N=429
Study 4
N=2806
B12: N=2806
-Beck 10+: N=429
MetS = metabolic syndrome
MINI = The Mini-International Neuropsychiatric Interview
Figure 1. Flow chart of studies I–IV.
4.2 Measurements of depression
The Beck Depression Inventory (BDI) was applied to assess DS. Subjects were asked to rate
21 items from 0 to 3 according to how they felt at that time. The items were summed as a
total score with a range from 0 to 63 (Beck et al. 1961, Beck and Beamesderfer 1974).
Subjects were categorized to have DS when they scored ³10 points in the BDI. The cut-off
point of 10 in the BDI has been shown to be a useful instrument for detecting depressive
symptoms in various adult populations (Beck et al. 1988, Timonen et al. 2006, Räikkönen et
al. 2007, Vanhala et al. 2009, Koponen et al. 2010, Korniloff et al. 2010, Mäntyselkä et al.
2011).
Furthermore, to determine the subtype of DS, a summary score of melancholic symptoms
in the BDI was calculated based on the DSM-IV-defined criteria (sadness, past failure, loss
of  pleasure,  guilty  feelings,  punishment  feelings,  loss  of  interest,  irritability,  change  in
22
sleeping and appetite). The subjects were defined to have DS with melancholic
characteristics when the number of melancholic symptoms exceeded the number of non-
melancholic symptoms (Sheehan et al. 1994, Steer et al. 1999, Ovaskainen et al. 2009,
Vanhala et al. 2009).
Furthermore,  those  cases  with  DS  (BDI  score ³ 10) were examined by an attending
psychiatrist, who carried out a normal psychiatric interview. In addition, board-certified
psychiatrists who were blind to the actual BDI score performed the Finnish version of the
MINI to establish the diagnosis of depression among participants with elevated DS.
4.3. Measurement of the MetS
The MetS was defined according to the modified National Cholesterol Education Program
(NCEP-ATPIII) criteria with a cut-off point of 100 mg/dL blood glucose (i.e. 5.6 mmol/l)
(Grundy et al. 2005). The use of lipid lowering, antihypertensive, antihyperglycemic, and
antidepressive medications was also recorded.
4.4 Assessment of dietary and folate intake
The Food Frequency Questionnaire (FFQ) was used to evaluate the diet over the previous
year (Männistö et al. 2006, Kaartinen et al. 2011). It is a well-validated method for
estimating dietary folate intake, and also the main method for estimating the role of diet in
the aetiology of chronic diseases (Kaartinen et al. 2011, Männistö et al. 1996). Nine possible
frequency categories  that  ranged from never  or  seldom to  at  least  six  times  per  day were
used to evaluate the consumption of 132 food items. Participants were also asked to record
those items not listed in the FFQ if they were frequently consumed. The size of the portion
was standardized for each food item (e.g., slice and glass). The FFQ was completed by the
subjects at the study centre under the surveillance of a trained study nurse. The nurse also
carefully checked the data. The software and National Food Composition Database of the
National Institute for Health and Welfare were used to derive the nutrient intakes from the
food information provided by the participants. The residual method was applied to adjust
the folate intake for the dietary energy intake (Willet and Stampfer 1998). Energy
adjustment is based on the assumption that a larger, more physically active person needs a
greater energy intake, which is associated with a greater absolute intake of all other
nutritients. Tertiles of gender-specific folate intake were used, because the mean energy-
adjusted folate intake was significantly lower in men than in women.
4.5 Laboratory analysis
The study laboratory sampling was conducted in accordance with the World Health
Organization MONICA protocol (World Health Organization 1988). Blood samples were
drawn  for  measurement  of  fasting  plasma  (fP)  glucose,  fS  triglycerides,  fS  HDL,  LDL
cholesterol concentrations, and serum vitamin B12 following an overnight fast.
Centrifugation was carried out within 1 h at room temperature to separate the serum and
plasma. The samples were then aliquoted into storage tubes and stored frozen at a
minimum of ?20 °C before transportation frozen to the National Institute for Health and
Welfare. The samples were stored at ?70 °C in the National Institute for Health and Welfare
until they were analyzed in the same laboratory. Participants were advised to contact their
own physician in the case of any abnormality in the laboratory results. The Laboratory of
Analytical Biochemistry at the National Public Health Institute, Helsinki, performed all
assays using a ci82000 analyzer (Abbott Laboratories, Abbott Park, IL).
The  Chemiluminescent  Microparticle  Immuno  Assay  (CMIA)  was  used  to  measure
serum vitamin B12 with a reference range of 138–652 pmol/L for the normal serum vitamin
B12 level. The interassay coefficients of variation (CV) of B12 vitamin were 6.2% and 5.0% at
the levels of 150 pmol/L and 380 pmol/L, respectively.
A hexokinase method (Abbott Laboratories, Abbott Park, IL) was used to determine
plasma  glucose,  and  serum  HDL  cholesterol  and  triglyceride  concentrations  were
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measured with enzymatic kits from Abbott Laboratories (Abbott Park, IL). The
concentrations of LDL cholesterol were calculated using the Friedewald formula
(Friedewald et al. 1972).
4.6 Other measurements
Height (in cm) was measured to the nearest 0.1 cm, and weight (in kg) was measured in
light  clothing  and  without  shoes  to  the  nearest  0.1  kg.  The  body  mass  index  (BMI)  was
calculated as weight in kilograms (kg) divided by the square of height in metres (m). Waist
circumference (in cm) was measured midway between the lowest rib margin and the iliac
crest. Blood pressure was measured twice in a sitting position after a minimum of 15
minutes of acclimization and before blood sampling using a mercury sphygmomanometer.
Education was assessed according to years of education. The participants were categorized
as married, single, separated or widowed according to information provided. Employment
status was asked, and the number of employed participants was counted. Self-administered
questionnaires were used to evaluate current smoking and alcohol consumption, which
were then dichotomized (no or yes).
The participants reported their leisure-time physical activity (LTPA) according to three
categories: 1) low: almost completely inactive (e.g., reading, watching television, or doing
some minor physical activity); 2) moderate: some physical activity more than 4 h per week
(e.g., walking, cycling, light gardening, fishing, or hunting); and 3) high: vigorous physical
activity more than 3 h per week or regular exercise or competitive sports several times a
week (e.g.,  running,  jogging,  skiing,  ball  games or  heavy gardening).  LTPA was assessed
with the question: “How much physical activity do you practice during leisure time?”
(Korniloff et al. 2010).
To establish a chronic diseases sum index, the participants were asked the question
“Have you had any of the following diseases that have been diagnosed or treated by a
doctor in the last 12 months.” Elevated blood pressure, heart failure, angina pectoris/other
cardiovascular event, diabetes, cancer, bronchial asthma/emphysema and rheumatoid
arthritis/other arthropathy/spinal diseases were included in the chronic diseases sum index,
which ranged from 0 to 7 (Mäntyselkä et al. 2011).
4.6 Statistical analysis
4.6.1 Study I
Differences between genders in characteristics were tested by t-tests and chi-squared tests.
Receiver operating characteristic (ROC) curves were constructed to determine the cut-off
point of BDI that corresponds to the MINI criteria, with bias-corrected bootstrap confidence
intervals (CIs). Sensitivity, specificity, positive and negative predictive values, the
likelihood ratio, and their 95% CI values were calculated. The difference between genders
in the area under the receiver operating characteristic curve (AUC) was evaluated by using
an algorithm suggested by DeLong with permutation (DeLong et al. 1988). The level of
statistical significance was set at 0.05
4.6.2 Study II
The results are expressed as means with SDs and 95% confidence intervals (CIs). The
groups  were  statistically  compared  using  chi-squared  tests  or  analysis  of  variance
(ANOVA). Logistic regression was used to model the prevalence of the MetS using
appropriate covariates. +
4.6.3 Study III
The  data  are  presented  as  means  with  standard  deviations  (SD)  and  counts  with
percentages. Statistical comparison between the groups was conducted using the chi-
squared test and t-test. Univariate and multivariate logistic regression analyses were
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performed to identify the appropriate predictors of depressive symptoms with linearity
contrast.
4.6.4 Study IV
The data are presented as means with standard deviations or counts with percentages.
Groups were statistically compared using the t-test, permutation test or chi-squared test, as
appropriate.
Multivariate logistic regression was used to analyse the relative risk ratios (RRR) and
their 95% confidence intervals (95% CI) for the presence of non-melancholic and
melancholic DS with appropriate contrasts. The multinomial (polytomous) logistic
regression model is an extension of the binomial logistic regression model and is used
when the dependent variable has more than two nominal (unordered) categories.
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5 RESULTS
5.1 Beck depression inventory (BDI) as a screening tool for depression (study I)
The distribution of baseline characteristics of the entire study population (n = 2840)
according to gender is presented in Table 8.
Table 8. Distribution of baseline characteristics of the entire study population (n = 2840) according to gender.
Variables Male
N = 1352
Female
N = 1488
Demographics
Age groups, n (%)
45–54 392 (29) 485 (33)
55–64 454 (34) 514 (35)
65–74 506 (37) 489 (33)
Marriage or common law marriage, n (%) 1092 (81) 1058 (71)
Educational status, n (%)
Basic education only 537 (40) 547 (37)
Vocational education 397 (29) 346 (23)
Upper secondary school 297 (22) 448 (30)
Higher education 108 (8) 139 (9)
Employed, n (%) 609 (45) 705 (47)
Clinical
Body mass index, kg/m2, mean (SD) 27.5 (4.2) 27.6 (5.3)
Waist, cm, mean (SD) 100 (12) 90 (13)
Blood pressure, mm/Hg, mean (SD)
Systolic 138 (19) 135 (19)
Diastolic 83 (10) 80 (9)
HDL cholesterol, mmol/l, mean (SD) 1.32 (0.32) 1.55 (0.34)
Total triglycerides, mmol/l, mean (SD) 1.49 (0.99) 1.28 (0.61)
Fasting plasma glucose, mmol/l, mean (SD) 6.43 (1.26) 6.03 (1.06)
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Metabolic syndrome, modified NCEP-ATPIII
criteria, n (%)
755 (56) 757 (51)
Use of antidepressive medication, n (%) 52 (4) 98 (7)
Lifestyle factors ./..
Current smoker, n (%) 336 (25) 289 (19)
Current use of alcohol, n (%) 970 (72) 729 (49)
Leisure time physical activity, n (%)
Low 254 (19) 265 (18)
Moderate 750 (55) 865 (58)
High 297 (22) 314 (21)
HDL = high-density lipoprotein
NCEP = National Cholesterol Education Program
Figure 2 illustrates the distribution of the BDI scores according to gender in the entire study
population (n = 2840).
The mean BDI score was 13.6 in males and 14.1 in females (p= 0.55).
To validate the diagnosis of depression, the MINI was performed for 162 out of 432
participants (57 males and 105 females) scoring ³10 in the BDI.
The characteristics of MINI-based depression in the present sample are presented in Table
9.
Leisure-time physical activity was more common among those without depression
compared  to  subjects  with  depression,  while  depressed  subjects  smoked  more  often  than
their non-depressed counterparts. The 162 study participants did not differ from cases not
attending the MINI (112 males and 158 females) with regard to socio-demographic
variables.
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Figure 2. Distribution of BDI scores according to gender in the entire study population (n = 2840).
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Table 9. Characteristics of the study population according to the depression status (study I).
MINI-based depression
Variable Not present
N = 117
Present
N = 45
P-value
Number of female, n (%) 76 (65) 29 (64) 0.95
Age, years, mean (SD) 62 (8) 59 (8) 0.091
Marriage or common law marriage, n (%) 80 (68) 32 (71) 0.74
Employment status, n (%) 0.095
Employed 36 (31) 13 (29)
Unemployed 3 (3) 5 (11)
Retired 78 (66)  (27 (60)
Educational status, n (%) 0.89
Basic education only 42 (36) 19 (42)
Vocational education 24 (21) 9 (20)
Upper secondary school 38 (32) 13 (29)
Higher education 13 (1)11 4 (9)
Leisure-time physical activity, n (%) 0.003
Low 29 (25) 22 (49)
Moderate 60 (51) 20 (44)
29
High 28 (24) 3 (7)
Current smoker, n (%) 20 (17) 14 (31) 0.05
Current use of alcohol, n (%) 97 (83) 37 (82) 0.92
The  sensitivity  and  specificity  curves  of  the  BDI  are  presented  in  Figure  3.  A  score  of  15
simultaneously maximized the sensitivity (0.56 (95% CI: 0.40 to 0.70)) and specificity (0.77
(95% CI: 0.68 to 0.84)). The PPV (positive predictive value) of 0.48 (95%CI: 0.34 to 0.62) and
the NPV (negative predictive value) of 0.82 (95%CI: 0.73 to 0.89) were favourable for the
cut-off  score  of  15  points  as  well  as  the  LR+  (likelihood  ratio  for  positive  result)  of  2.41
(95%CI: 1.58 to 3.67) as compared to other cut-off levels.
Beck-score
10 12 14 16 18 20 22 24 26 28 30 32
%
0
10
20
30
40
50
60
70
80
90
100
Sensitivity
Specificity
Figure 3. Sensitivity and specificity curves of the depression diagnosis on the basis of
the BDI. The reference test is the MINI (study I).
5.2 Prevalence of metabolic syndrome (MetS) in subjects with melancholic and non-
melancholic depressive symptoms (study II)
The number of subjects with the MetS in the entire study population according to the BDI
scores is presented in Figure 4.
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Figure 4. Number of subjects with the MetS in the entire study population according to scores in
the Beck Depression Inventory (BDI) (study II).
The study population (N = 2820) included 432 subjects scoring ³10 on the BDI, who were
further  divided  into  groups  with  predominantly  non-melancholic  DS  (N  =  293)  and
melancholic DS (N = 139). The groups with non-melancholic and melancholic DS and those
without DS differed significantly from each other in several demographic and biochemical
variables (Table 10). The BMI, as well as the fasting plasma glucose and triglyceride
concentrations were highest in the group with non-melancholic DS (Table 10). Differences
were  also  seen  in  smoking  and  LTPA.  Smoking  was  most  common  in  subjects  with
melancholic DS compared to those with non-melancholic DS or to subjects without DS. A
high level of physical activity was least common among those with non-melancholic DS
(Table 10), while those with melancholic DS or without DS formed the reference
population. LTPA was lower among the two depressed groups than in non-depressed
population. The use of antidepressive medication was not higher in the group with
melancholic DS compared to those with non-melancholic characteristics (p = 0.10, age and
sex adjusted).
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Table 10. Demographic, biochemical and lifestyle variables and use of antidepressive
medication by those in the identified depressive symptom groups (study II).
Variables Depressive symptoms P value*
A
N = 293
B
N = 139
No
N = 2388
Age, years, (SD) 61 (8) 61 (9) 59 (8) <0.001
Female, n (%) 180 (61) 83 (60) 1220 (51) 0.001
Body mass index, kg/m2 29.0 (6.1) 27.7 (4.3) 27.3 (4.7) <0.001
Waist, cm, (SD)
Male 104 (14) 104 (14) 100 (11) <0.001
Female 95 (16) 91 (11) 90 (13) <0.001
Blood pressure, mmHg, (SD):
Systolic (SD) 137 (19) 135 (18) 137 (19) 0.067
Diastolic (SD) 81 (10) 80 (9) 82 (10) 0.44
HDL cholesterol, mg/dL, (SD):
Male 49.5 (11.2) 48.3 (12.4) 51.0 (12.4) 0.13
Female 58.4 (12.4) 58.4 (12.0) 60.3 (13.1) 0.16
Total triglycerides, mg/dL, (SD): 132.0 (71.7) 124.0 (56.7 120.5 (73.5)) 0.015
Fasting plasma glucose, mg/dL,
(SD):
114.6 (25.1) 110.1 (18.2) 111.9 (20.7) 0.048
Smoking, n (%) 72 (25) 41 (30) 510 (21) 0.001
Using alcohol, n (%) 156 (53) 72 (52) 1471 (62) 0.20
LTPA, n (%) <0.001
Low 97 (33) 46 (33) 376 (16)
Moderate 153 (52) 66 (47) 1396 (60)
High 24 (8) 22 (16) 565 (24)
Antidepressive medication,
N (%)
47 (16) 32 (23) 71(3) <0.001
* Adjusted for age and sex.
A = non-melancholic depressive symptoms
B = melancholic depressive symptoms
LTPA = leisure time physical activity
HDL = high-density lipoprotein
The  prevalence  of  the  MetS  according  to  the  depressive  symptom  status  in  males  and
females is presented in Table 11.
The highest prevalence of the MetS (69%) was found in both males (95% CI 60 to 77) and
females (95% CI 62 to 76) in the subgroup of non-melancholic DS compared to those with
melancholic DS (61%; 95% CI 47 to 74 vs. 51%; 95% CI 39 to 62) or to those without DS
(54%; 95% CI 52 to 57 vs. 48%; 95% CI 45 to 51) (Table 11). No interaction between sex and
depressive  symptom  status  was  found  in  the  groups  with  DS.  Except  for  the  glucose
criterion in males, the highest prevalence for each criterion was found among the persons
with non-melancholic DS (see article II, Figure 2).
Table 11. Prevalence of metabolic syndrome according to depressive symptom status
in males and females (study II).
Male
% (95% CI)
Female
% (95% CI)
RR (95% CI)
BDI < 10 54 (52 to 57) 48 (45 to 51) 1.13 (1.04 to 1.22)
Depressive symptoms:
non-melancholic 69 (60 to 77) 69 (62 to 76) 1.00 (0.86 to 1.17)
melancholic 61 (47 to 74) 51 (39 to 62) 1.20 (0.89 to 1.62)
RR = relative risk
Subjects with non-melancholic DS had two-fold higher odds (2.10; 95% CI 1.62 to 2.73, p <
0.001) for the MetS in the logistic regression analyses adjusted for age and sex, whereas
melancholic DS were not associated with the MetS (OR 1.15; 95% CI 0.81 to 1.61, p = 0.44)
when subjects without DS formed the reference group. Non-melancholic DS were
associated with the MetS (OR 1.84; 95% CI 1.20 to 2.80, p = 0.005) when compared to the
melancholic group (see article II, Table 2).
Non-melancholic DS were associated with the MetS (OR 1.68; 95% CI 1.16 to 2.22, p <
0.001), whereas melancholic DS did not associate with the MetS (OR 0.92; 95% CI 0.64 to
1.13, p = 0.67) when multivariate logistic regression analysis adjusted for sex, age, smoking,
alcohol use and LTPA was applied. Non-melancholic DS were also associated with the
MetS (OR 1.87; 95% CI 1.19 to 2.93, p = 0.006) when compared to the melancholic group (see
article II, Table 2).
5.3 Association between folate intake and melancholic depressive symptoms (study III)
The study population (N = 2806) included 429 subjects with a BDI score ³10. The general
characteristics of the two subgroups with BDI scores <10 or ³10 are presented in Table 12.
Participants with elevated DS were less educated, more likely to be older or female. They
also had a higher BMI, were unmarried or unemployed, and their level of physical activity
was lower. Subjects with DS used less alcohol than their non-depressed counterparts (Table
12).
The population with BDI ³10 was further divided into groups with predominantly
melancholic (N = 138) and non-melancholic DS (N = 291).
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Table 12. Distribution of baseline factors according to depressive symptom status
(study III).
Depressive symptoms status P-value
BDI score ?10
N = 429
BDI score <10
N = 2377
Female, n (%) 263 (61) 1215 (51) <0.001
Age, years, mean (SD) 61 (9) 59 (8) <0.001
Body Mass Index (kg/m2), mean (SD) 28.6 (5.6) 27.3 (4.7) <0.001
Education years, mean (SD) 10 (8.13) 11 (8.14) <0.001
Marital status, n (%) <0.001
Married 286 (67) 1842 (78)
Single 47 (11) 181 (8)
Separated 61 (14) 215 (9)
Widowed 33 (8) 130 (5)
Employed, n (%) 113 (26) 1229 (52) <0.001
Current smoker, n (%) 111 (26) 508 (21) 0.038
Using alcohol, n (%) 225 (52) 1465 (62) <0.001
Leisure time physical activity, n (%) <0.001
Low 141 (35) 375 (16)
Moderate 218 (54) 1391 (60)
High 46 (11) 561 (24)
Chronic diseases sum index (0–7), mean
(SD)
1.12 (1.30) 0.60 (1.06) <0.001
Use of antidepressive medication, n (%) 77 (18) 71 (3) <0.001
The mean energy-adjusted folate intake was 434 ± 93 µg/day among those without DS (BDI
< 10) and 421 ± 103 µg/day in subjects with DS (BDI ³ 10) (p = 0.007) (Figure 5).
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Furthermore, subjects with melancholic DS had a lower mean energy-adjusted folate intake
as compared to subjects with non-melancholic DS (408 ± 84 µg/day vs. 427 ± 110 µg/day, p
= 0.007).
Men had a lower mean energy-adjusted folate intake than women (406 ± 83 µg/day vs. 455
± 98 µg/day, p < 0.001).
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Figure 5. Estimated energy-adjusted folate intake of the subjects according to the Beck
Depression Inventory score. The curve with 95% confidence band was derived from a
quadratic model (study III).
Melancholic DS were linearly and inversely associated with gender-specific tertiles of the
folate intake (p for linearity = 0.005), while non-melancholic DS were not (p for linearity =
0.12). A linear association was also found between DS and gender-specific tertiles of folate
intake (p for linearity = 0.003) (Figure 6).
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Figure 6. Panel A: Prevalence of DS (depressive symptoms, Beck ³10) with 95%CIs according
to gender-specific folate intake tertiles
Panel B: Prevalence of DS with melancholic and non-melancholic characteristics with
95%CIs according to gender-specific folate intake tertiles
P-values introducing non-adjusted linearity (study III).
The OR for melancholic DS was 0.52 (95% CI 0.33 to 0.82) for the high folate intake
tertile versus the low tertile (p for linearity = 0.005) in the unadjusted model, while the
unadjusted ORs for non-melancholic DS remained nonsignificant. After several
adjustments, the OR for melancholic DS was still 0.55 (95% CI 0.34 to 0.90) for the high
folate intake tertile versus the low tertile (p for linearity = 0.018). The multivariate ORs for
non-melancholic DS were nonsignificant (Table13).
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Table 13. Association between different dietary folate intake tertiles (I = low, II =
medium and III = high) and both non-melancholic and melancholic depressive
symptoms  (DS) (study III).
BDI ?10
Non-melancholic DS  Melancholic DS
OR (95% CI) P-value
For linearity
 OR (95% CI) P-value
for linearity
Model 1
I 1 (Reference) 0.12  1 (Reference) 0.005
II 0.69 (0.51 to 0.94)  0.81 (0.54 to 1.21)
III 0.79 (0.59 to 1.06)  0.52 (0.33 to 0.82)
Model 2
I 1 (Reference) 0.08  1 (Reference) 0.006
II 0.68 (0.50 to 0.93)  0.83 (0.55 to 1.26)
III 0.76 (0.56 to 1.03)  0.53 (0.33 to 0.83)
Model 3
I 1 (Reference) 0.47  1 (Reference) 0.024
II 0.76 (0.55 to 1.05)  0.96 (0.63 to 1.48)
III 0.89 (0.64 to 1.23)  0.57 (0.35 to 0.92)
Model 4
  I 1 (Reference) 0.24  1 (Reference) 0.018
  II 0.73 (0.52 to 1.01)  0.95 (0.62 to 1.46)
  III 0.82 (0.59 to 1.14)  0.55 (0.34 to 0.90)
Model 1: unadjusted
Model 2: adjusted for age and antidepressive medication
Model 3: adjusted for age, antidepressive medication, BMI, leisure-time physical activity,
alcohol, smoking, marital status, and years of education
Model 4: adjusted for age, BMI, leisure-time physical activity, alcohol, smoking, marital
status, years of education and chronic diseases
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5.4 Association between vitamin B12 levels and melancholic depressive symptoms (study
IV)
The study population was the same as in study III (Table 12).
A difference between males and females was found in vitamin B12 levels (312 ± 171 pmol/L
vs. 343 ± 168 pmol/L, p < 0.001). Figure 7 illustrates the distribution of S-B12 levels among
men and women according to depressive symptom status.
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Figure 7. Distribution of S-B12 levels among men and women according to depressive symptom status (study
IV).
Subjects with depressive symptoms were subdivided into groups with predominantly
melancholic (N = 138) and non-melancholic DS (N = 291) to further examine the vitamin B12
levels. An independent linearly inverse association between the B12 level tertiles and
melancholic  depressive  symptoms  was  found  in  the  multinomial  regression  analysis:  the
relative risk ratio (RRR) was 2.75 (95% CI 1.66 to 4.56, p for linearity <0.001) in the lowest
vitamin  B12 level tertile as compared to the highest (Table14). No association between B12
vitamin tertiles and non-melancholic DS was detected, since the RRR for the lowest vitamin
B12 level tertile versus the highest was 1.20 (95%CI 0.86 to 1.66, p for linearity 0.28) (Table
14).
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Table 14. Relative risk ratios for having non-melancholic or melancholic depressive
symptoms and their 95% confidence intervals (95% CI) from multinomial regression
analysis (study IV).
Variables NmDS versus  BDI <
10
RRR (95% CI)
P-value MDS versus
BDI < 10
RRR (95 % CI)
P-value
Vitamin B12 tertiles*
  I 1 (reference) 0.28# 1 (reference) <0.001#
  II 1.01 (0.72 to 1.41) 1.90 (1.21 to 3.22)
  III 1.20 (0.86 to 1.66) 2.75 (1.66 to 4.56)
Male sex 0.59 (0.44 to 0.79) <0.001 0.82 (0.54 to 1.23) 0.34
Age 1.02 (1.00 to 1.04) 0.041 1.02 (1.00 to 1.05) 0.091
BMI 1.02 (1.00 to 1.05) 0.11 0.98 (0.94 to 1.02) 0.32
Smoking 1.23 (0.88 to 1.71) 0.23 1.41 (0.91 to 2.20) 0.13
Using alcohol 1.09 (0.81 to 1.45) 0.59 0.84 (0.56 to 1.26) 0.39
LTPA <0.001# 0.006#
  I 1 (reference) 1 (reference)
  II 0.50 (0.37 to 0.68) 0.42 (0.27 to 0.64)
  III 0.24 (0.15 to 0.39) 0.43 (0.24 to 0.76)
Years of education 0.98 (0.94 to 1.02) 0.24 1.00 (0.95 to 1.06) 0.99
Living alone 1.29 (0.95 to 1.75) 0.10 1.93 (1.30 to 2.88) 0.001
Energy intake 1.00 (1.00 to 1.00) 0.90 1.00 (1.00 to 1.00) 0.74
Use of antidepressive
medication
5.51 (3.55 to 8.54) <0.001 9.45 (5.63 to 15.86) <0.001
Chronic diseases sum index 1.41 (1.26 to 1.59) <0.001 1.21 (1.02 to 1.45) 0.031
* Gender specific tertiles: Male I > 340 pmol/L, II = 255–340 pmol/L, III < 255 pmol/L;
Female I > 380 pmol/L, II = 280–379 pmol/L, III = <280 pmol/L.
# P for linearity.
RRR = relative risk ratio
BDI = Beck Depression Inventory
NmDS = non-melancholic depressive symptoms
MDS = melancholic depressive symptoms
BMI = body mass index
LTPA = leisure-time physical activity
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6 DISCUSSION
6.1 Pivotal findings
According to  first  study,  a  BDI  score  of  15  simultaneously  maximized the  sensitivity  and
specificity of the BDI in detecting depression compared to other suggested cut-off points of
14 and 18. In addition, the area under the ROC curves did not differ between genders.
Thus, these results suggest that the BDI with a cut-off point of 15 is a fairly valid screening
instrument for the detection or exclusion of depression in population-based subjects. On
the other hand, when taking into account the findings of this study and others, the BDI
alone cannot provide an accurate diagnosis of depression or replace clinical diagnostic
interviews.
Study  II  had  two  novel  findings.  Firstly,  the  prevalence  of  the  MetS  was  higher  in
subjects with predominantly non-melancholic DS compared to those with melancholic DS.
Secondly,  study  II  reported  that  the  subjects  with  non-melancholic  DS  also  had  two-fold
higher odds for the MetS, whereas melancholic DS were not associated with the MetS,
when  those  without  DS  formed  the  reference  group.  When  compared  to  the  melancholic
group, non-melancholic DS were associated with the MetS. Correspondingly, this result
remained significant after multivariate logistic regression analysis adjusted for sex, age,
smoking,  alcohol  use  and  LTPA.  The  components  of  the  MetS  explaining  this  finding
include  the  elevated  fasting  glucose  and  triglyceride  levels  in  the  group  with  non-
melancholic DS, and the higher waist circumference in females within the same group. The
finding displayed no interaction with sex.
Study III showed that the unadjusted OR for melancholic DS was almost 50% lower for
the  high  folate  intake  tertile  versus  the  low  tertile,  while  the  unadjusted  OR  for  non-
melancholic DS remained nonsignificant. The result remained constant even after several
adjustments. DS also linearly associated with gender-specific tertiles of folate intake.
Furthermore, melancholic DS were linearly inversely associated with gender-specific
tertiles of folate intake, while non-melancholic DS were not.
Vitamin B12 levels showed an independent linearly inverse association with the risk of
melancholic DS. The relative risk ratio (RRR) for melancholic DS was almost three-fold
higher  in  the  lowest  vitamin B12 level tertile as compared to the highest when those with
melancholic DS were compared to those without DS. There was no association between B12
vitamin tertiles and subjects with non-melancholic DS.
6.2. Study population, methods and design
The study population consisted of middle-aged and elderly Caucasian subjects from three
hospital districts of Finland, namely Pirkanmaa, Southern Ostrobothnia and Central
Finland. The prevalence of the MetS was also common in both sexes for the same reason
(56% for males and 51% for females). The strengths of the study include a large population-
based sample from the National Population Register containing middle-aged and elderly
subjects with a substantial prevalence of DS. The study population was also geographically
representative, covering both urban and rural districts in three study areas. In addition, a
WHO-based study methodology was used, and the laboratory analysis was carried out in
one series.  However, the study group can be considered genetically homogeneous, which
limits the possibility to generalize the results to a wider, genetically more heterogeneous
sample. The use of clinical DSM-IV-based Mini-International Psychiatric Interview (MINI)
as a validation measure for depression is considered as a strength in study I. The FFQ used
in study III is also a well-validated method for estimating the dietary folate intake. It
describes the habitual diet, which is often more relevant in the aetiological evaluation of
chronic diseases than the current, short-term diet.
Some additional limitations of the present study warrant consideration. Firstly, in study I,
only those who scored ³ 10  in  the  BDI  were  invited  for  a  further  examination,  at  which
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point only 38 % attended the MINI, which has to be considered as a limitation. Moreover,
the time difference between BDI scoring and clinical examination was in some cases several
weeks. Secondly, in studies II–IV, the detection of DS was based on a self-rating scale, and
not on a diagnostic interview for depression. The MINI-based diagnosis was not applied in
studies II–IV, because a sufficient number of subjects with DS of either melancholic or non-
melancholic  characteristics  was  needed to  enhance the  comparison of  the  results  of  those
studies with former reports. Thirdly, as the study population was in advanced middle age,
the generalizability of the results to younger age groups may be limited. Fourthly, the FFQ
has certain limitations. When using the FFQ, subjects may also tend to overestimate foods
that are considered healthy and underestimate those regarded as unhealthy. It mainly
collects data on food groups and not on specific food items. Moreover, the presented food
list limits flexibility compared to handwritten diet records; for example, information on
cooking methods is lost and subjects must make their usual portion sizes conform with
those listed on the form. Finally, due to the cross-sectional study design, we cannot make
inferences of causality.
6.3 Beck Depression Inventory (BDI) as a screening tool for depression (study I)
According to the present study, a BDI score of 15 simultaneously maximized the sensitivity
and specificity compared to the widely used cut-off points of 14 and 18, which are quite
close to this cut-off point. With the cut-off of 15, PPV was 0.48, NPV 0.82 and LR+ 2.41.
The  diagnostic  performance  of  the  BDI  was  weaker  in  the  present  study  than  in  the
previous two studies, since the sensitivity and PPV for a cut-off point of 15 in the BDI were
0.56 and 0.48 in the present study, whereas Nuevo et al. (2009) presented 0.63 and 0.60 and
Lasa et al. (2000) 1.00 and 0.72. However, the present NPV of 0.82 was similar to that found
in the study by Nuevo et al. (0.83), while the specificity was 0.77 compared to 0.81.
Likelihood ratios were not presented by Nuevo et al. or Lasa et al. Compared to other
epidemiological studies evaluating a screening test, the encountered sensitivity, specificity
and PPV were not on a high level. The sensitivity of over 0.70 and specificity of over 0.90
would validate the BDI as a screening test for major depression, while the PPV of 0.71
found here may be poor for clinical practice (Lustman et al. 1997). However, low PPVs of a
screening  test  can  be  justified  if  early  detection  is  essential  (e.g.  to  reduce  suicidality)
(Lustman et al. 1997). In addition, an NPV value of 0.93 has been justified (Lustman et al.
1997), while NPV was 0.82 in the present study for a cut-off point of 15. PPV and NPV are
also directly proportional to the prevalence of the condition, namely depression, as PPV
tends to  be  higher  and NPV lower  when the  prevalence  increases.  The present  likelihood
ratio of 2.41 means that a cut-off point of 15 in the BDI only results in a small increase in the
probability of detecting depression.
The study population was older (mean age 61 years for males and 62 years for females)
than in the study by Nuevo et al. (respective means 42 years and for 43.5 years) and that by
Viinamäki et al. (mean age of the sample 44 years) (Nuevo et al. 2009, Viinamäki et al.
2004). In the study by Lasa et al., only the age of the entire screened population was
reported, of which nearly a third was between 18 and 29 years and the rest between 30 and
64 years (Lasa et al. 2000). The cut-off point preferred here is similar to that found in the
study by Viinamaki et al. (15 vs. 14). However, they conducted a smaller number of
interviews compared to the present study, and the material consisted of medical patients.
The study by Lasa et al. included a smaller number of cases attended from a rather restricted
geographic area, although it was performed among the general population. A lower cut-off
point of 12/13 showed 100% sensitivity and 99% specificity. The recent study by Nuevo et
al. with a larger number of subjects interviewed in a relatively restricted geographic area in
Finland among the general population suggested a higher cut-off point (17/18 on the BDI)
than the present study, but the inclusion criterion for the more exact diagnostic interview
was higher (BDI 13), favouring a higher cut-off point (Nuevo et al. 2009).  In addition to
different samples, one possible reason for the variation in cut-off points may lie in the
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differing diagnostic evaluation. The present study used the DSM-IV-based clinical Finnish
version of the MINI as a validation tool for depression, while Lasa et al. and Nuevo et al.
used the SCAN interview based on the ICD-10 criteria (Lasa et al. 2000, Nuevo et al. 2009).
The Beck Depression inventory is focused on symptoms of sadness, pessimism, past
failure, loss of appetite, loss of pleasure, self-dislike, self-criticism and suicidal thoughts or
wishes, which reflect the DSM-IV criteria for major depressive disorder. However, it is
widely agreed that the Beck Depression Inventory alone cannot provide an accurate
diagnosis of depression or replace clinical diagnostic interviews (Gilbody et al. 2008).
According to  the  results  of  the  present  study,  the  BDI  with a  cut  of  point  of  15  is  a  valid
screening instrument for the detection or exclusion of depression.
6.4 Prevalence of the metabolic syndrome (MetS) in subjects with melancholic and non-
melancholic depressive symptoms (study II)
This  study  had  two  novel  findings.  Firstly,  the  prevalence  of  the  MetS  was  higher  in
subjects with predominantly non-melancholic DS compared to those with melancholic DS.
Secondly, the odds for the MetS were two-fold higher in subjects with predominantly non-
melancholic DS, whereas melancholic DS were not associated with the MetS when subjects
without DS formed the reference group. Certain components of the MetS explained the
finding: the elevated fasting glucose and triglyceride levels in the group with non-
melancholic DS, and the higher waist circumference in females within the same group. The
result displayed no interaction with sex, and remained statistically significant even after
multiple adjustments, suggesting a genuine difference between the non-melancholic and
melancholic  subgroups.  This  is  partly  in  line  with  the  finding  that  perceived  depression
detected by a BDI score ³14/15 was associated with elevated blood glucose among men and
a large waist circumference among women (Miettola et al. 2008).
No other studies have examined the prevalence of the MetS among populations with
non-melancholic or melancholic DS. However, Lamers and co-workers demonstrated in a
cross-sectional study based on a clinical sample and healthy controls that the MetS was
more common in the severe atypical depressive class compared to the severe melancholic
depressive class. The prevalence of abdominal obesity and hypertriglyceridemia was also
higher among subjects in the severe atypical depressive class than in the severe melancholic
class (Lamers et al. 2010). Interestingly, women with undifferentiated and atypical features
of major depressive disorder exhibited a higher BMI, as well as whole body and abdominal
fat mass compared to healthy controls (Cizza et al. 2012).
However, the results of this study are not fully comparable with previous studies due to
differences in the study settings and subgroup definitions. Nevertheless, the results from
both  of  the  previous  studies  and  from  the  present  study  suggest  differences  in  lipid
metabolism between subtypes of DS. Taking into account the results of this and the studies
by Lamers  et  al.  and Cizza et  al.,  DS with non-melancholic  characteristics  and the  severe
atypical depressive class may have common features in terms of the higher prevalence of
the MetS, or higher BMI, waist circumference and triglyceride levels compared to those
with more melancholic features. An alternative explanation for these to some extent
congruent results may be the similarity of the non-melancholic group in this study and the
atypical depressive population in the other settings.
The only longitudinal study by Vanhala and co-workers reported the highest risk for the
MetS among women in the subgroup with more melancholic symptoms, which may at least
in part be explained by the more severe DS among women than men, and by the long-term
use of antidepressive medications during the seven-year study period (Vanhala et al. 2009).
On the other hand, a recent study revealed that the association between DS and MetS could
not be explained by antidepressant medication (Pyykkönen et al. 2012).
In the present study population, physical activity was lower in both groups with DS, which
is  noteworthy,  since  physical  exercise  could  effectively  relieve  depressive  symptoms
(Leppämäki et al. 2002). Moreover, an earlier study based on the same material as the
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present one demonstrated that the prevalence of simultaneous MetS and DS was higher in
participants with low LTPA compared with participants with high LTPA (Korniloff et al.
2010). It was also observed that smoking was most prevalent in the group with melancholic
DS, which is in line with other studies reporting that depressed subjects are more likely to
smoke (van Gool et al. 2003, Bonnet et al. 2005). The underlying mechanisms involved may
include a shared genetic vulnerability to both nicotine dependence and depression, or the
use of smoking as a form of self-medication (Lerman et al. 1998).
The results suggest that the liability to the MetS is particularly associated with non-
melancholic DS, which may suggest possible differences between types of DS in the
susceptibility to the MetS. The role of a higher waist circumference in females among the
subgroup of non-melancholic DS is also interesting, as inflammation and the induction of
oxidative and nitrosative stress may be connected with depression, and may provide an
explanation for the association between depression and obesity and the MetS (Maes et al.
2011).  The  results  of  the  present  study  can  be  of  clinical  importance  if  the  subtype  of  DS
should be taken into account in the selection of antidepressive medication as, for instance,
tricyclic  antidepressant  (TCA)  users  more  often  gain  weight  or  have  the  MetS  (McElroy
2009, van Reedt et al. 2010b). Mirtazapine may be placed between the selective serotonin
reuptake inhibitors (SSRI) and TCAs in terms of the relative risk of weight gain (Fava 2000).
In addition, paroxetine may be more likely to cause weight gain than the other SSRIs in the
long term (Fava 2000, Gartlehner et al. 2008).
6.5 Association between folate intake and melancholic depressive symptoms (study III)
The novel finding of the present study is that the folate intake was associated with
melancholic DS but not with non-melancholic DS after taking into account a large number
of  potential  confounders.  This  result  is  in  line  with  the  monoamine  hypothesis  of
depressive disorders connecting a low folate intake with diminished serotonin synthesis
(Stahl 2008). On the other hand, elevated homocysteine levels, mainly caused by a
deficiency in folate or vitamin B12 levels, may have associations with inflammatory
parameters (Gori et al. 2005, Mabrouka et al. 2010). Therefore, a low folate intake may be
associated with depression via homocysteine and inflammation.
Depression itself is accompanied by inflammation (Maes 2011). To our knowledge, no
previous studies have evaluated the folate intake in a melancholic or non-melancholic
depressive  population,  but  the  results  of  the  present  study  are  consistent  with  a  clinical
study among adult outpatients with major depressive disorder, in which subjects with low
folate  levels  were  more  likely  to  have  melancholic  depression  than  those  with  normal  or
higher folate levels (Fava et al. 1997).
A linearly inverse association was also detected between DS and gender-specific tertiles
of folate intake in the whole study population. These results in relation to the role of a
lower  folate  intake  and  DS  are  consistent  with  previously  published  population-based
studies. However, methodological differences exist regarding the lack of sub-typing of the
DS, and evaluation of dietary exposure. For example, Finnish population-based studies on
middle-aged and elderly men revealed a protective effect of folate intake on depressive
symptoms originally in a cross-sectional setting, and subsequently an effect on depression
in a follow-up setting (Tolmunen et al. 2003, Tolmunen et al. 2004). A low folate intake was
associated with depression among currently smoking men and men with low anxiety levels
in a cross-sectional study among university graduates (Sanchez-Villegas et al. 2009).
According to a Japanese cross-sectional study conducted on adolescent boys and girls, a
higher folate intake was independently correlated with a lower prevalence of depressive
symptoms  (Murakami  et  al.  2010).  Contradictory  results  exist,  since  an  American
longitudinal study reported that the intake of folate was not associated with DS over time
in community-residing older adults (Skarupski et al. 2010). Therefore, evidence for the
relationship between folate intake and depression remains ambiguous and cannot be
considered conclusive.
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An association between folate intake and depression has been suggested to be most
apparent in aging populations (Reynolds 2002). In addition, several factors may influence
the absorption and metabolism of folate. Firstly, alcohol can have impact on the absorption
and metabolism of folate, leading to a reduction in the potential beneficial effects of folate
intake on depression (Koehler et al. 2001, Chiuve et al. 2005). Secondly, cigarette smoking
increases folate requirements by interfering with folate utilization and/or metabolism
(Bailey 1990, Piyathilake et al. 1994), which may lead to a higher prevalence of folate
deficiency among smokers. However, in the present study, the linear association of folate
intake  tertiles  and  DS  with  melancholic  characteristics  also  remained  constant  in  the
multivariate model including antidepressive medication.
The results of the present study suggest an association between a low folate intake and
DS, which is congruent with some previous findings. In this study, a linear association was
observed between folate intake tertiles and DS with melancholic characteristics, but not
with non-melancholic characteristics. These findings suggest that folate may play a role in
the pathogenesis of DS, which may associate with melancholic characteristics.
6.6 Association between vitamin B12 levels and melancholic depressive symptoms (study
IV)
The novel finding according to the present population-based study was that vitamin B12
levels showed an independent linearly inverse association with the risk of melancholic DS,
but not with non-melancholic DS when those without DS formed the reference group. This
result is in line with the monoamine hypothesis of depressive disorders connecting a low
vitamin  B12 level  with  diminished  synthesis  of  serotonin  and  other  monoamines  (Stahl
2008). Another link may be via inflammation, as a deficiency of vitamin B12 can  lead  to
elevated homocysteine levels which, according to some data, could be associated with
inflammatory parameters (Gori et al. 2005, Mabrouka et al. 2010). In this way, depression
and vitamin B12 levels could be associated with each other. An approximately three-fold
higher RRR was observed in the current study for melancholic DS in the lowest vitamin B12
tertile  compared to  those  without  DS.  Thus,  the  risk  is  congruent  with  the  results  from a
recent study in which vitamin B12 deficiency appeared to be associated with the occurrence
of DS (OR = 2.68) (Ng et al. 2009). In two earlier studies, the risk levels were similar, but
somewhat lower (OR 2.05 and 1.64, respectively) (Penninx et al. 2000, Tiemeier et al. 2002).
The association between vitamin B12 levels and depression is to some extent
controversial, since incongruent results have also been published. All the studies showing
positive relationships between vitamin B12 levels and DS or depressive disorders have been
conducted among older populations (Penninx et al. 2000, Tiemeier et al. 2002, Kim et al.
2008, Ng et al. 2009), while most previous population-based studies showing no association
have had younger populations than that of the present study (Bjelland et al. 2003, Morris et
al. 2003, Beydoun et al. 2010). Some exceptions exist, since an American and an Australian
study failed to detect this association among older populations (Lindeman et al. 2000,
Sachdev et al. 2005). With regard to these partly inconsistent results, the age of the study
population and the distribution of depression subtypes are important. However,
methodological differences in subject selection and in the measurement of depressive
symptoms or depression, or in the B12 status, may also contribute to differing findings. In
Finland, 11–21% of persons were reported to have DS when assessed according to the BDI
with the same, rather low cut-off score of 10 points, which is in line with the prevalence of
15% recorded in the present study (Vaananen et al. 2008,Vanhala et al. 2009).
On the basis of previous results, the elderly may be more vulnerable to low vitamin B12
levels, because vitamin B12 deficiency is more common in the aged. Its prevalence was 12%
in the Finnish population (aged 65–100 years) compared to the finding that 5% of
Canadians (age 6–79 years) were vitamin B12 deficient (Loikas et al. 2007, Mac Farlane et al.
2011). In younger adults, lifestyle factors such as smoking, alcohol consumption and a
vegetarian  diet  are  known  risk  factors  for  vitamin  B12 deficiency (Herrmann and Geisel
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2002, Wolters et al. 2004). However, no such association was recorded in an aged Finnish
population (Loikas et al. 2007).  No particular risk group for lower vitamin B12 levels could
be defined among the aged (Loikas et al. 2007). On the other hand, gastrointestinal diseases,
especially atrophic gastritis in the elderly, may increase the risk of vitamin B12 deficiency
(Loikas et al. 2007). The association with age may have an alternative explanation as well,
since the brain effects of low vitamin B12 may not manifest until much later in life.
A higher risk of melancholic depressive symptoms was associated with lower vitamin
B12 levels in the current study. These findings suggest that vitamin B12 may contribute to the
pathogenesis of DS.
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6.7 Implications for clinical practice and research
The results of study I warrant that the routine use of the BDI in the screening of DS among
population-based samples should be carefully evaluated, as its ability to detect depression
is not very robust. Overall, studies are needed to evaluate the correlation between the BDI
and diagnostic interviews in the diagnostic process of depression in population-based
samples. Compared to the current study, future studies should include a higher proportion
of subjects who attend the diagnostic interview to validate the diagnosis of depression.
According to study II, the possible susceptibility to the MetS among those having DS
with non-melancholic characteristics may highlight that the subtype of DS should be taken
into account in the selection of antidepressive medication as, for instance,  tricyclic
antidepressant users more often gain weight or have the MetS. Those administered
mirtazapine and paroxetine may also have a higher tendency to suffer from weight
problems. In addition, the tendency for the MetS may warrant the screening or follow-up of
the MetS and its components in this particular group of DS. From the research point of
view, the result supports the contention that depression, as a whole, is not a homogeneous
entity. Several subtypes may exist, such as those with non-melancholic or melancholic
features.  These  possible  subtypes  should  be  studied  more  thoroughly  with  regard  to
genetic, hormonal and metabolic parameters. Overall, the finding of study II should be
verified and replicated in samples with different ages and ethnic groups, and further
studies are therefore needed.
The findings of studies III and IV correlate a low folate intake and low vitamin B12 levels
with  the  risk  of  melancholic  DS,  which  may  also  have  practical  implications.  Clinicians
should  take  into  account  the  patient’s  folate  or  vitamin  B12 status  when  examining  or
treating patients with depression, especially with melancholic characteristics. At the same
time, it would be adequate to evaluate the dietary patterns of patients with DS. The results
of studies II, III and IV support the idea of different depressive subtypes, and also highlight
the importance of genetically screening these different depressive subgroups. In addition,
the  possible  role  of  both  folate  intake  and  vitamin  B12 levels in the pathogenesis of
depression warrant research in this field. Nevertheless, further studies are needed to
evaluate the possible associations between DS and the intake of folate or vitamin B12 levels
among populations comprising different ages or various ethnic groups and depressive
subtypes.
Finally, due to the cross-sectional design of the study, inferences of causality cannot be
made. Therefore, longitudinal, population-based studies with a sufficient number of
participants in different age and ethnic groups are warranted to evaluate the prevalence of
the MetS, and the role of folate intake or vitamin B12 levels  among  subjects  with
predominantly melancholic or with non-melancholic characteristics. Their target may be to
evaluate whether depression with melancholic or non-melancholic subtypes might have
different aetiological roles in terms of proinflammation and the diet.
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7 SUMMARY
This study was conducted to evaluate the value of the BDI as a screening instrument for
depression using the clinical DSM-IV-based Mini-International Psychiatric Interview
(MINI) as a validating measure. It also evaluated the role of the MetS and its components,
folate intake, and vitamin B12 levels in groups with predominantly melancholic or non-
melancholic DS.
The study population was enrolled as a part of the national type 2 diabetes prevention
programme (FIN-D2D), as a project of the Finnish community-based type 2 diabetes
prevention programme, aimed at exploring the ways to implement preventive methods for
type 2 diabetes on a national level. Three hospital districts of Finland, namely Pirkanmaa,
Southern  Ostrobothnia  and  Central  Finland,  were  selected  for  the  efficacy  survey,  which
was carried out between October and December 2007. A representative random sample of
4500 subjects aged 45–74 years, stratified according to gender, 10-year age groups (45–54,
55–64, and 65–74 years) and the three geographical areas, was selected from the National
Population Register in August 2007. Of the 4500 persons who were invited by mail to the
health examination, 2868 participated (attendance 64%).
DS was assessed by using the BDI, and a cut-off point of 10 was applied to capture DS.
A summary score of DSM-IV-based criteria of melancholic symptoms in the BDI was used
to determine the subtype of DS by dividing the participants with elevated DS into
melancholic and non-melancholic depressive symptom subgroups. In the evaluation of the
MetS,  the  modified NCEP-ATPIII  criteria  with  a  cut-off  point  of  100  mg/dL (5.6  mmol/L)
blood glucose were applied. The diet over the previous 12 months was assessed using the
FFQ. Serum vitamin B12 was measured using the CMIA. The study methods followed the
World Health Organization MONICA protocol.
The study demonstrated that BDI with a cut-off point of 15 is a valid screening
instrument for the detection or exclusion of depression in population-based subjects.
However, the BDI alone cannot provide an accurate diagnosis of depression or replace
clinical diagnostic interviews.
The prevalence of the MetS was higher in subjects with predominantly non-melancholic
DS compared to those with melancholic DS or to those without DS. The odds for the MetS
were two-fold higher in subjects with predominantly non-melancholic DS, whereas
melancholic DS were not associated with the MetS when subjects without DS formed the
reference  group.  When  compared  to  the  melancholic  group,  non-melancholic  DS  were
associated with the MetS. The components of the MetS explaining the finding include the
elevated fasting glucose and triglyceride levels in the group with non-melancholic DS, and
the higher waist circumference in females within the same group. These results suggest
that the liability to the MetS is particularly associated with non-melancholic DS, which may
suggest possible differences among the types of DS in the susceptibility to the MetS.
In  this  study,  the  folate  intake  was  associated  with  melancholic  DS  but  not  with  non-
melancholic DS. The result remained constant even after several adjustments. DS was also
linearly inversely associated with gender-specific tertiles of folate intake.
Vitamin B12 levels demonstrated an independent linearly inverse association with the
risk of melancholic DS. The RRR for the melancholic DS population to belong to the lowest
vitamin B12 level tertile (compared to the highest) was almost three-fold higher when those
with melancholic DS were compared to those without DS. There was no association
between B12 vitamin tertiles and subjects with non-melancholic DS. The findings of the
present study suggest that folate intake and vitamin B12 may contribute to the pathogenesis
of DS, which may be associated with melancholic characteristics.
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The metabolic syndrome, low folate 
intake or lower vitamin B12 levels 
may be associated with depression. 
However, the impact of melancholic or 
non-melancholic depressive symptoms 
has not been evaluated. 
The results of this study support the 
use of the Beck Depression Inventory 
as a screening tool for depressive 
symptoms. A higher risk of the 
metabolic syndrome was associated 
with non-melancholic depressive 
symptoms.  In addition, those with a 
lower folate intake or lower vitamin 
B12 levels had a higher risk of 
melancholic depressive symptoms. 
